<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">60742</article-id><article-id pub-id-type="doi">10.7554/eLife.60742</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-197619"><name><surname>Johnson</surname><given-names>Sean L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197620"><name><surname>Ranxhi</surname><given-names>Bedri</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2508-731X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197621"><name><surname>Libohova</surname><given-names>Kozeta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-197622"><name><surname>Tsou</surname><given-names>Wei-Ling</given-names></name><email>wtsou@wayne.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-196231"><name><surname>Todi</surname><given-names>Sokol V</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4399-5549</contrib-id><email>stodi@wayne.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Pharmacology, Wayne State University</institution><addr-line><named-content content-type="city">Detroit</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Neurology, Wayne State University</institution><addr-line><named-content content-type="city">Detroit</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>VijayRaghavan</surname><given-names>K</given-names></name><role>Senior Editor</role><aff><institution>National Centre for Biological Sciences, Tata Institute of Fundamental Research</institution><country>India</country></aff></contrib><contrib contrib-type="editor"><name><surname>VijayRaghavan</surname><given-names>K</given-names></name><role>Reviewing Editor</role><aff><institution>National Centre for Biological Sciences, Tata Institute of Fundamental Research</institution><country>India</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>21</day><month>09</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e60742</elocation-id><history><date date-type="received" iso-8601-date="2020-07-06"><day>06</day><month>07</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-08-30"><day>30</day><month>08</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Johnson et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Johnson et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-60742-v1.pdf"/><abstract><p>Spinocerebellar ataxia type 3 (SCA3) belongs to the family of polyglutamine neurodegenerations. Each disorder stems from the abnormal lengthening of a glutamine repeat in a different protein. Although caused by a similar mutation, polyglutamine disorders are distinct, implicating non-polyglutamine regions of disease proteins as regulators of pathogenesis. SCA3 is caused by polyglutamine expansion in ataxin-3. To determine the role of ataxin-3’s non-polyglutamine domains in disease, we utilized a new, allelic series of <italic>Drosophila melanogaster</italic>. We found that ataxin-3 pathogenicity is saliently controlled by polyglutamine-adjacent ubiquitin-interacting motifs (UIMs) that enhance aggregation and toxicity. UIMs function by interacting with the heat shock protein, Hsc70-4, whose reduction diminishes ataxin-3 toxicity in a UIM-dependent manner. Hsc70-4 also enhances pathogenicity of other polyglutamine proteins. Our studies provide a unique insight into the impact of ataxin-3 domains in SCA3, identify Hsc70-4 as a SCA3 enhancer, and indicate pleiotropic effects from HSP70 chaperones, which are generally thought to suppress polyglutamine degeneration.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>ataxia</kwd><kwd>aggregation</kwd><kwd>neurodegeneration</kwd><kwd>deubiquitinase</kwd><kwd>proteostasis</kwd><kwd>machado-joseph disease</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>D. melanogaster</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R01NS08677</award-id><principal-award-recipient><name><surname>Todi</surname><given-names>Sokol V</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006710</institution-id><institution>Wayne State University</institution></institution-wrap></funding-source><award-id>Competitive Graduate Research Assistantship</award-id><principal-award-recipient><name><surname>Johnson</surname><given-names>Sean L</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Pathogenesis in Spinocerebellar Ataxia Type 3 is enhanced by the heat-shock protein family member, Hsc70-4, uncovering new mechanisms of toxicity for this disease and suggesting pleiotropic roles for chaperones.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Spinocerebellar ataxia type 3 (SCA3; also known as Machado-Joseph disease) is the most frequent dominant ataxia worldwide. SCA3 is caused by CAG repeat expansion in the gene <italic>ATXN3</italic> that is normally 12–42 repeats long but is expanded to ~60–87 repeats in patients (<xref ref-type="bibr" rid="bib76">Todi et al., 2007b</xref>; <xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>). This triplet repeat encodes a polyglutamine (polyQ) tract in the protein, ataxin-3, a deubiquitinase (DUB; <xref ref-type="fig" rid="fig1">Figure 1</xref>) implicated in protein quality control and DNA repair (<xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>; <xref ref-type="bibr" rid="bib16">Dantuma and Herzog, 2020</xref>). The precise molecular details of SCA3 pathogenesis remain unclear.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Ataxin-3 domains impact its polyQ toxicity.</title><p>(<bold>A</bold>) Diagram of ataxin-3. Josephin: deubiquitinase domain necessary for ataxin-3's ability to cleave ubiquitin bonds (<xref ref-type="bibr" rid="bib87">Winborn et al., 2008</xref>). UbS: ubiquitin-binding site (<xref ref-type="bibr" rid="bib55">Nicastro et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Nicastro et al., 2009</xref>); UIM: ubiquitin-interacting motif (<xref ref-type="bibr" rid="bib87">Winborn et al., 2008</xref>); RKRR: amino acid sequence necessary for ataxin-3 to bind directly to VCP, known as VCP-binding motif, VBM (<xref ref-type="bibr" rid="bib10">Boeddrich et al., 2006</xref>). QQQ: polyQ that is expanded in SCA3 (<xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>). Also shown is the amino acid sequence of human ataxin-3 used. (<bold>B</bold>) Summary of transgenic fly lines, mutations, and abbreviations. (<bold>C</bold>) Longevity results when pathogenic ataxin-3 versions are expressed pan-neuronally in adults. P values: log-rank tests with Holm-Bonferroni adjustment. Italicized P value: not statistically significant. (<bold>D</bold>) Means -/+ SD from negative geotaxis tests. Groups are the same as in (<bold>C</bold>). P values: one-tailed, Student’s t-tests comparing lines to control flies of the same day and time point. ‘One-tailed’ tests were chosen based on the outcomes from longevity data in panel (<bold>C</bold>), which indicated specific directionality in expectations. If no P value is noted, it was equal to or greater than 0.05. Exact P values are given in other cases. The total number of flies in each group is shown in panels. For panel (D), the number of independent groups of flies per genotype was: Ctrl: 5, Intact: 5, Inactive: 6, UbS2*: 5, VBM*: 5. Repeats were biological replicates.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Data related to <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60742-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Ataxin-3 domains impact the toxicity of its polyQ-expanded variant in glia.</title><p>(<bold>A</bold>) Longevity curves from adults expressing the noted versions of ataxin-3 in all fly glia, throughout development and in adults. These are the same lines as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. P values are from log-rank tests with Holm-Bonferroni adjustment. P values in italics are not statistically significant. There is no statistical difference for 100% death between flies expressing ‘Intact’ versus ‘Inactive’, even though 50% lethality is different. This is because each vial with flies is treated as one individual and for statistical purposes the day when all flies are dead is considered, not the rate of death over the course of time for each vial. (<bold>B</bold>) Negative geotaxis assay comparing motility of flies not expressing any pathogenic ataxin-3 versus flies expressing pathogenic ataxin-3 with mutated VBM in all glial cells. Driver, as in panel (<bold>A</bold>), was repo-Gal4. No statistical differences are observed at any time point between the groups based on two-tailed Student’s t-tests. We selected to conduct this assay for the VCP-binding mutations since in longevity curves we noticed no significant differences in the longevity of flies not expressing pathogenic ataxin-3 compared to ones expressing the SCA3 protein with the VCP-binding mutation. Note: The ‘Intact’ line shown here is a different transgenic line than the one we generated for the polyQ studies concerning the UIMs that are shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> and beyond. Those lines (<xref ref-type="fig" rid="fig2">Figure 2</xref> and on) have a ‘CAGCAA’ repeat for reasons summarized in main text, compared to a pure 'CAG' repeat for all lines shown in <xref ref-type="fig" rid="fig1">Figure 1</xref> and in this figure, which were generated for prior work. The lines generated for <xref ref-type="fig" rid="fig2">Figure 2</xref> also have an optimized Kozak sequence. As we showed earlier (<xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>), the ‘CAGCAA’ repeat-harboring ‘Intact’ line is at higher protein levels and is more toxic than the pure 'CAG' repeat shown here. For all the work in this study, isogenic sets are compared only to one another, that is, none of the lines shown here and in <xref ref-type="fig" rid="fig1">Figure 1</xref> is directly compared to lines in <xref ref-type="fig" rid="fig2">Figure 2</xref> and beyond, since these lines were conceptualized as isogenic sets from the beginning. However, we remind the reader that all ataxin-3 lines are inserted into the same chromosomal site of <italic>Drosophila</italic>, attP2, in the same orientation and as a single copy number.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig1-figsupp1-v1.tif"/></fig></fig-group><p>SCA3 is one of the nine neurodegenerative disorders caused by abnormal polyQ expansion in diverse proteins (<xref ref-type="bibr" rid="bib76">Todi et al., 2007b</xref>; <xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>). The polyQ family includes Huntington’s disease (HD), SCAs 1, 2, 3, 6, 7, and 17, Dentatorubral–pallidoluysian atrophy, and Kennedy’s disease. Together, HD and SCA3 are the two most common among the nine known polyQ diseases. Although each polyQ disorder is caused by the aberrant lengthening of the same domain, they are clinically distinct diseases (<xref ref-type="bibr" rid="bib76">Todi et al., 2007b</xref>; <xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>; <xref ref-type="bibr" rid="bib52">Nath and Lieberman, 2017</xref>; <xref ref-type="bibr" rid="bib59">Pérez Ortiz and Orr, 2018</xref>; <xref ref-type="bibr" rid="bib44">Lieberman et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Klockgether et al., 2019</xref>). Fundamental to polyQ disorders is the role of protein context, i.e. regions outside of the polyQ that modulate the properties of the elongated tract (<xref ref-type="bibr" rid="bib76">Todi et al., 2007b</xref>; <xref ref-type="bibr" rid="bib52">Nath and Lieberman, 2017</xref>; <xref ref-type="bibr" rid="bib59">Pérez Ortiz and Orr, 2018</xref>; <xref ref-type="bibr" rid="bib44">Lieberman et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Klockgether et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Blount et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>). It is the protein context that differentiates polyQ diseases; why, for example, expansions in ataxin-3 cause SCA3 instead of another disorder. While studies of other polyQ diseases provided insight into the role of protein context in polyQ neurodegeneration (<xref ref-type="bibr" rid="bib76">Todi et al., 2007b</xref>; <xref ref-type="bibr" rid="bib52">Nath and Lieberman, 2017</xref>; <xref ref-type="bibr" rid="bib59">Pérez Ortiz and Orr, 2018</xref>; <xref ref-type="bibr" rid="bib44">Lieberman et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Klockgether et al., 2019</xref>), the protein context for SCA3 has not been clarified. For instance, in SCA1, the nuclear localization signal directs its disease protein, ataxin-1, to the nucleus and is necessary for pathogenesis (<xref ref-type="bibr" rid="bib59">Pérez Ortiz and Orr, 2018</xref>; <xref ref-type="bibr" rid="bib38">Klement et al., 1998</xref>). Studies on SCA7 also identified interactions with other proteins that show a role for non-polyQ domains in the toxicity of its disease protein, ataxin-7 (<xref ref-type="bibr" rid="bib52">Nath and Lieberman, 2017</xref>; <xref ref-type="bibr" rid="bib44">Lieberman et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Duncan et al., 2013</xref>). Another good case of polyQ protein biology and expression pattern being connected to phenotype is Kennedy's disease. In this disorder, polyQ expansion occurs near the amino terminus of the androgen receptor (AR), which results in a partial loss of AR function that leads to androgen insensitivity, as well as proteotoxicity. AR is expressed in motor neurons of the spinal cord and the brainstem, where it mediates neurotrophic responses. It is these neurons that degenerate in Kennedy's disease (<xref ref-type="bibr" rid="bib76">Todi et al., 2007b</xref>; <xref ref-type="bibr" rid="bib44">Lieberman et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Giorgetti et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Lieberman et al., 2002</xref>; <xref ref-type="bibr" rid="bib43">Lieberman et al., 2014</xref>).</p><p>To understand the role of protein context in SCA3, we focused on the domains of ataxin-3. Ataxin-3 contains a ubiquitin-protease (Josephin) domain on its N-terminal half (<xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>; <xref ref-type="bibr" rid="bib16">Dantuma and Herzog, 2020</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Within it are the catalytic triad that enables ataxin-3 to cleave ubiquitin bonds, as well as two ubiquitin-binding sites (UbS) that either interact with ubiquitin (UbS1), or with ubiquitin and the proteasome-associated protein, Rad23 (UbS2; <xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>; <xref ref-type="bibr" rid="bib16">Dantuma and Herzog, 2020</xref>). Downstream are two ubiquitin-interacting motifs (UIMs 1 and 2), followed by a site that binds the AAA ATPase, VCP (VCP-binding motif; VBM), and the polyQ tract (<xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>; <xref ref-type="bibr" rid="bib16">Dantuma and Herzog, 2020</xref>). At the end resides a third UIM (UIM3) (<xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>; <xref ref-type="bibr" rid="bib16">Dantuma and Herzog, 2020</xref>). In another, less common isoform UIM3 is replaced by a hydrophobic C-terminus (<xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>; <xref ref-type="bibr" rid="bib31">Harris et al., 2010</xref>; <xref ref-type="bibr" rid="bib37">Kawaguchi et al., 1994</xref>). UIMs enable ataxin-3 to bind poly-ubiquitin (<xref ref-type="bibr" rid="bib87">Winborn et al., 2008</xref>; <xref ref-type="bibr" rid="bib77">Todi et al., 2009</xref>; <xref ref-type="bibr" rid="bib78">Todi et al., 2010</xref>).</p><p>We previously examined the role of three domains of ataxin-3 in its pathogenicity: UbS2, VBM, and the catalytic site. UbS2 regulates ataxin-3 turnover and toxicity (<xref ref-type="bibr" rid="bib8">Blount et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>); the VBM controls ataxin-3 aggregation and toxicity, but not turnover (<xref ref-type="bibr" rid="bib8">Blount et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>); and the catalytic site is necessary for ataxin-3's inherent neuroprotective functions (<xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib79">Tsou et al., 2013</xref>). These findings led us to examine the role of other domains of ataxin-3 by using novel, isogenic lines of the model organism, <italic>Drosophila melanogaster</italic>. Here, we show that toxicity from ataxin-3's polyQ tract is markedly impacted by the UIMs. Whereas the isolated polyQ is decidedly pathogenic, UIM addition enhances toxicity. Mutating the UIMs of full-length, pathogenic ataxin-3 renders it less harmful. UIMs interact with heat shock protein cognate 4 (Hsc70-4), which enhances ataxin-3 aggregation and toxicity in a manner dependent on these ubiquitin-binding domains. Additional studies indicate that Hsc70-4 enhances the toxicity of other polyQ proteins and provide a comprehensive view of the relative impact of various ataxin-3 domains on its pathogenicity. We introduce unique genetic tools to understand SCA3 biology and to discover and optimize therapeutic options for it. Our studies provide novel insight into protein context in SCA3 and highlight Hsc70-4 as a new target for intervention.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The modulatory role of ataxin-3’s domains on its toxicity</title><p>Protein context is a key determinant of polyQ degeneration (<xref ref-type="bibr" rid="bib76">Todi et al., 2007b</xref>; <xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>; <xref ref-type="bibr" rid="bib16">Dantuma and Herzog, 2020</xref>; <xref ref-type="bibr" rid="bib52">Nath and Lieberman, 2017</xref>; <xref ref-type="bibr" rid="bib59">Pérez Ortiz and Orr, 2018</xref>; <xref ref-type="bibr" rid="bib44">Lieberman et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Klockgether et al., 2019</xref>; <xref ref-type="bibr" rid="bib26">Giorgetti et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Lieberman et al., 2014</xref>), but its importance in SCA3 has not been investigated systematically. We previously examined the role of non-polyQ domains of ataxin-3, UbS2 (<xref ref-type="bibr" rid="bib8">Blount et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>), and VBM (<xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Prior work from us, spearheaded by pioneering studies from the Bonini lab, also showed that the catalytic site of ataxin-3 is important for toxicity (<xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib79">Tsou et al., 2013</xref>; <xref ref-type="bibr" rid="bib86">Warrick et al., 2005</xref>). However, the contribution of different domains to ataxin-3 pathogenicity has not been investigated side-by-side.</p><p>Using isogenic fly lines (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), we examined the toxicity of pathogenic ataxin-3 when expressed pan-neuronally in adults using the binary, Gal4-UAS system of expression (<xref ref-type="bibr" rid="bib12">Brand and Perrimon, 1993</xref>; <xref ref-type="bibr" rid="bib11">Brand et al., 1994</xref>) and a driver that requires the drug, RU486 to induce transgenes (<xref ref-type="bibr" rid="bib56">Nicholson et al., 2008</xref>; <xref ref-type="bibr" rid="bib57">Osterwalder et al., 2001</xref>; <xref ref-type="bibr" rid="bib62">Roman and Davis, 2002</xref>; <xref ref-type="bibr" rid="bib71">Sujkowski et al., 2015</xref>). We selected this approach as SCA3 is adult-onset and progressive and also because neurons are the type of cell impacted. We compared the following full-length, human ataxin-3 versions: intact domains, catalytically inactive, mutated UbS2 (UbS2* <xref ref-type="bibr" rid="bib8">Blount et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>), and mutated VBM (VBM* <xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="fig" rid="fig1">Figure 1B</xref>). The polyQ repeat is 78–80, within-patient range (<xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>). Each transgene is inserted into the same chromosomal location, attP2, as one copy and in the same orientation, leading to similar expression (<xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Tsou et al., 2015b</xref>; <xref ref-type="bibr" rid="bib82">Tsou et al., 2016</xref>; <xref ref-type="bibr" rid="bib9">Blount et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Groth et al., 2004</xref>).</p><p>Adult, pan-neuronal expression of pathogenic ataxin-3 with intact domains caused early lethality (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Catalytically inactive ataxin-3 led to significantly shorter lifespan, as did the version with mutated UbS2. Mutating the VBM led to markedly longer lifespan compared to ‘intact’. Still, flies expressing pathogenic ataxin-3 with mutated VBM did not reach normal longevity (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). These data were complemented by negative geotaxis assays (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). We observed reduced motility with flies expressing pathogenic ataxin-3 ‘intact’ and further impaired motility with those expressing inactive ataxin-3 or ataxin-3 with mutated UbS2. On the other hand, pan-neuronal expression of pathogenic ataxin-3 with mutated VBM did not significantly impact motility.</p><p>Next, we examined the effect of the same ataxin-3 transgenes in glial cells to obtain information on toxicity from pathogenic ataxin-3 in this cell type. Overall trends were similar to neuronal cells: catalytically inactive and UbS2-mutated ataxin-3 led to increased toxicity compared with pathogenic ataxin-3 with intact domains. But, unlike in neurons, in glial cells we did observe a statistical difference in toxicity between pathogenic ataxin-3 with mutated catalytic site and the one with mutated UbS2. There was no statistical difference between controls not expressing pathogenic ataxin-3 and flies expressing pathogenic ataxin-3 with mutated VBM both in terms of longevity (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) and motility (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). These findings highlight a need to explore the role of glia in SCA3.</p><p>Based on these collective data, we conclude that domains outside of ataxin-3's polyQ play significant modulatory roles in pathogenicity. These outcomes led us to ask: what is the role of the most common domain of ataxin-3, the UIM, in SCA3?</p></sec><sec id="s2-2"><title>UIMs enhance toxicity of the isolated polyQ of ataxin-3</title><p>To conduct an initial examination of ataxin-3 UIMs in SCA3, we synthesized transgenes that encode its isolated polyQ by itself or with the sequential addition of UIMs, including a full-length version (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We generated isogenic lines that integrated each transgene into locus attP2, same as flies in <xref ref-type="fig" rid="fig1">Figure 1</xref>. The polyQ for these new flies is encoded by alternating CAGCAA repeats. Long, pure CAG tracts can lead to mRNA-based toxicity (<xref ref-type="bibr" rid="bib40">Li et al., 2008</xref>) and unconventional translation of non-polyQ frames (<xref ref-type="bibr" rid="bib3">Bañez-Coronel et al., 2015</xref>; <xref ref-type="bibr" rid="bib91">Zu et al., 2011</xref>; <xref ref-type="bibr" rid="bib92">Zu et al., 2018</xref>). Our approach mitigates both possibilities (<xref ref-type="bibr" rid="bib40">Li et al., 2008</xref>; <xref ref-type="bibr" rid="bib24">Figura et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Green et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Martí, 2016</xref>; <xref ref-type="bibr" rid="bib65">Shieh and Bonini, 2011</xref>; <xref ref-type="bibr" rid="bib66">Sobczak et al., 2003</xref>; <xref ref-type="bibr" rid="bib67">Sobczak and Krzyzosiak, 2005</xref>; <xref ref-type="bibr" rid="bib69">Stochmanski et al., 2012</xref>), allowing us to focus solely on toxicity from the polyQ and specific domains. To the best of our knowledge, ours is the first instance that this approach is undertaken to dissect in detail the role of regions surrounding a polyQ in an intact organism.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>UIMs modulate toxicity of the isolated polyQ of ataxin-3.</title><p>(<bold>A</bold>) Diagram (top) and abbreviations (bottom) for transgenes used. The polyQ of ataxin-3 has a lysine interruption after the first three glutamines (QQQKQQQQ…), highlighted in yellow. (<bold>B</bold>) Summary of results when the noted transgenes are expressed in fly tissues. 1st, 2nd, and 3rd instars are progressive larval stages as flies develop from embryos to pupae. Results in table are representative of independent crosses conducted at least five times each. (<bold>C</bold>) Graphical summary of results from (<bold>B</bold>). Solid color denotes primary observations. (<bold>D</bold>) Photos of adult eyes expressing transgenes through GMR-Gal4. Photos are representative of independent crosses conducted at least five times. Protein levels are shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>. (<bold>E</bold>) Longevity of flies expressing transgenes pan-neuronally in adults. P values: log-rank tests with Holm-Bonferroni adjustment. Italicized P value: not statistically significant.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Data related to <xref ref-type="fig" rid="fig2">Figure 2</xref> - part 1.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60742-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Data related to <xref ref-type="fig" rid="fig2">Figure 2</xref> - part 2.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60742-fig2-data2-v1.pdf.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Levels of polyQ proteins, related to <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title><p>Western blots from lysates of whole, dissected fly heads; 25 heads per group. We caution here that the comparison of overall polyQ proteins is not precise, especially concerning polyQ80-UIM3, which leads to markedly severe eye degeneration. The reason for generating these truncated lines was to conduct an initial exploration of the role of UIMs on the isolated polyQ of ataxin-3. The main focus of this work is full-length ataxin-3 and the role of UIMs in its pathogenicity, explored in subsequent figures. Future work will dissect how individual UIMs impact various properties of the isolated polyQ80 in a tissue- and age-dependent manner.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig2-figsupp1-v1.tif"/></fig></fig-group><p>The isolated polyQ80 was more toxic than full-length, pathogenic ataxin-3 when expressed in all tissues or only in neurons (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). This pattern was reversed in glia; full-length ataxin-3 was more problematic than polyQ80 in these cells, highlighting a need to better understand glial response to polyQ proteins. Intriguingly, polyQ80 was generally less toxic than the same peptide with appended UIMs when expressed everywhere, selectively in neurons, or in glia; addition of UIM3 appeared particularly pathogenic (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). Eye-restricted expression of these transgenes also led to variable toxicity, with UIM3 addition being more problematic than the isolated polyQ80 or polyQ80 with all UIMs (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><p>Gal4 drivers above enable transgene expression during development and in adults. Because, as mentioned above, SCA3 is adult-onset, we also investigated the effect of polyQ80 without and with UIMs when expressed pan-neuronally only in adults. PolyQ80 was noticeably less toxic than versions with UIMs (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Flies expressing Q80-UIM3 or UIM1-2-Q80 lived longer than those expressing polyQ80 with all UIMs (<xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><p>There were tissue-dependent variations in toxicity from the above constructs. For example, Q80-UIM3 was markedly more toxic in fly eyes compared to the polyQ80 alone or with the addition of other UIMs (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), whereas polyQ80 with all three UIMs was the most toxic species in adult neurons (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). These are intriguing findings that require future attention; also, they are not dissimilar from the neuronal-glial differences we observed in <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, and <xref ref-type="fig" rid="fig2">Figure 2B</xref>. These outcomes highlight the utility of the new fly models that we have generated to understand tissue-selective toxicity in vivo in the future. Collectively, data in <xref ref-type="fig" rid="fig2">Figure 2</xref> indicate a regulatory role for UIMs in the pathogenicity of the expanded polyQ of ataxin-3, and led us to explore them in the full-length protein.</p></sec><sec id="s2-3"><title>UIMs of full-length ataxin-3 regulate toxicity and aggregation</title><p>To investigate a regulatory role for the UIMs in the pathogenicity of full-length ataxin-3, we generated an additional transgenic line that expresses human ataxin-3 with mutated UIMs (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). This line was created through site-directed mutagenesis of the plasmid used to generate flies in <xref ref-type="fig" rid="fig2">Figure 2A</xref>. The mutations that we selected were previously shown to disable the ability of ataxin-3 UIMs to bind poly-ubiquitin (<xref ref-type="bibr" rid="bib87">Winborn et al., 2008</xref>; <xref ref-type="bibr" rid="bib77">Todi et al., 2009</xref>; <xref ref-type="bibr" rid="bib78">Todi et al., 2010</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mutating the UIMs of full-length, pathogenic ataxin-3 decreases its toxicity.</title><p>(<bold>A</bold>) Amino acid sequence of full-length, pathogenic ataxin-3 and UIM mutations. (<bold>B</bold>) Summary of results when ataxin-3 flies, or non-expressing controls, are monitored during development and in adulthood. Results are representative of independent crosses conducted at least five times each. (<bold>C</bold>) Longevity of flies expressing transgenes pan-neuronally, throughout development and in adults. P value: log-rank test. (<bold>D</bold>) Negative geotaxis assays of adults expressing pathogenic ataxin-3 and their non-expressing controls. Shown are means -/+ SD. P values: two-tailed, Student’s t-tests comparing flies at each time point to their corresponding, non-expressing controls. We selected ‘two-tailed’ tests since we did not know how ‘UIM*’ would perform compared to ‘Ctrl’. If no P value is noted, it was equal to or greater than 0.05. Exact P values are given in other cases. The number of groups of flies tested per genotype was: Ctrl: 6, SCA3: 8, SCA3UIM*: 6. Repeats were biological replicates.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Data related to <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60742-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig3-v1.tif"/></fig><p>Expression of pathogenic ataxin-3 with mutated UIMs was consistently and markedly less toxic than its counterpart with intact UIMs in all of the tissues tested (<xref ref-type="fig" rid="fig3">Figure 3B,C</xref>). Motility assays also showed that adults expressing UIM-mutated ataxin-3 retained mobility longer than adults expressing pathogenic ataxin-3 with intact UIMs (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). We conclude that mutating its UIMs renders ataxin-3 significantly less pathogenic.</p><p>Next, we examined if reduced toxicity from UIM mutations reflected changes in ataxin-3 levels or aggregation. Mutating the UIMs does not cause loss of ataxin-3 protein (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). We used three antibodies for this assay: a rabbit monoclonal antibody that recognizes the C-terminal HA tag; a mouse monoclonal antibody that recognizes an epitope upstream of UIM1-2 (1H9); and a rabbit polyclonal antibody generated against full-length ataxin-3 (Machado-Joseph disease [MJD]; <xref ref-type="bibr" rid="bib58">Paulson et al., 1997</xref>). While there is variance in the exact species recognized by each antibody, overall we conclude that mutating the UIMs does not deplete ataxin-3 protein. Differences in species likely stem from epitopes recognized by each antibody, SDS solubility of different ataxin-3 species, and epitope exposure on PVDF membrane.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Mutating the UIMs of pathogenic ataxin-3 decreases its aggregation.</title><p>(<bold>A</bold>) Western blots from simple lysates of adults expressing transgenes pan-neuronally. Red arrows: likely proteolytic products of ataxin-3 that we observe sometimes. (<bold>B</bold>) Cytoplasmic/nuclear fractionation of lysates from adults expressing transgenes pan-neuronally. Histograms: quantification of images from the left and other, independent biological replicates. Means -/+ SD. P value: two-tailed Student’s t-test. Italicized P value denotes lack of statistical significance. The entire ataxin-3 signal in each lane was used for calculations, from the main band to the top. (<bold>C</bold>) Soluble/pellet centrifugation of lysates from adults expressing the noted transgenes. Histograms are from the left and other, independent biological repeats. Shown are means -/+ SD. P value: two-tailed, Student’s t-test. The entire ataxin-3 signal in each lane was used for calculations, from the main band to the top. (<bold>D</bold>) Filter-trap assay of lysates from adult flies expressing transgenes pan-neuronally. Each image is from an independent biological repeat. Histograms: quantification of images from left. Means -/+ SD. P value: two-tailed, Student’s t-test. Black arrows in panels: main ataxin-3 band. Blue arrows in panels: ubiquitinated ataxin-3. SDS-soluble and -resistant labels are based on prior work with ataxin-3 (<xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>; <xref ref-type="bibr" rid="bib77">Todi et al., 2009</xref>; <xref ref-type="bibr" rid="bib78">Todi et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Tsou et al., 2013</xref>).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Data related to <xref ref-type="fig" rid="fig4">Figure 4</xref> - part 1.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60742-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Data related to <xref ref-type="fig" rid="fig4">Figure 4</xref> - part 2.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60742-fig4-data2-v1.pdf.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig4-v1.tif"/></fig><p>Prior work showed that nuclear presence of polyQ disease-causing proteins is a critical regulator of pathogenicity (<xref ref-type="bibr" rid="bib44">Lieberman et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Klement et al., 1998</xref>; <xref ref-type="bibr" rid="bib6">Bichelmeier et al., 2007</xref>; <xref ref-type="bibr" rid="bib46">Macedo-Ribeiro et al., 2009</xref>). Based on subcellular fractionation, there was no significant difference in distribution between ataxin-3 with intact or mutated UIMs (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). However, according to two different assays, mutating the UIMs rendered pathogenic ataxin-3 less aggregation-prone. Centrifugation-based protocols and filter-trap assays both showed higher aggregation of pathogenic ataxin-3 with intact UIMs (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>). PolyQ protein aggregation is a hallmark of this family of diseases (<xref ref-type="bibr" rid="bib76">Todi et al., 2007b</xref>; <xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>; <xref ref-type="bibr" rid="bib52">Nath and Lieberman, 2017</xref>; <xref ref-type="bibr" rid="bib44">Lieberman et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Klockgether et al., 2019</xref>; <xref ref-type="bibr" rid="bib58">Paulson et al., 1997</xref>). In our <italic>Drosophila</italic> studies, aggregation of pathogenic ataxin-3 and other polyQ proteins precedes toxicity; also, the level of aggregation mirrors the extent of their pathogenicity (<xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>; <xref ref-type="bibr" rid="bib79">Tsou et al., 2013</xref>; <xref ref-type="bibr" rid="bib81">Tsou et al., 2015b</xref>; <xref ref-type="bibr" rid="bib82">Tsou et al., 2016</xref>). Based on data from <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>, we conclude that the UIMs of pathogenic ataxin-3 enhance its aggregation and toxicity in <italic>Drosophila</italic>.</p></sec><sec id="s2-4"><title>UIMs mediate ataxin-3 interaction with Hsc70-4</title><p>UIMs exist in proteins with various functions and interact with poly-ubiquitin (<xref ref-type="bibr" rid="bib16">Dantuma and Herzog, 2020</xref>; <xref ref-type="bibr" rid="bib2">Andersen et al., 2005</xref>; <xref ref-type="bibr" rid="bib47">Marmor and Yarden, 2004</xref>; <xref ref-type="bibr" rid="bib90">Zheng and Shabek, 2017</xref>; <xref ref-type="bibr" rid="bib18">Dikic et al., 2009</xref>). The UIMs of ataxin-3 indeed bind poly-ubiquitin (<xref ref-type="bibr" rid="bib87">Winborn et al., 2008</xref>; <xref ref-type="bibr" rid="bib77">Todi et al., 2009</xref>; <xref ref-type="bibr" rid="bib78">Todi et al., 2010</xref>). Still, we wondered whether proteins other than ubiquitin also interact with ataxin-3 through UIMs. After all, at least one other ubiquitin-binding domain on ataxin-3, UbS2, interacts with ubiquitin and a non-ubiquitin protein, Rad23 (<xref ref-type="bibr" rid="bib8">Blount et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib55">Nicastro et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Nicastro et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Nicastro et al., 2005</xref>) To find proteins that interact with ataxin-3 through its UIMs, we homogenized flies expressing ataxin-3 pan-neuronally and depleted resulting lysates of poly-ubiquitin by using tandem ubiquitin binding entities (TUBEs; Methods). Afterward, we immunopurified (IP-ed) ataxin-3 from the supernatants and resolved all proteins on an SDS-PAGE gel (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). We observed a band above ataxin-3 that was present with intact UIMs but not as clearly visible when they were mutated. Mass spectrometry from the dissected regions yielded heat shock protein cognate 4 (Hsc70-4) only in the presence of ataxin-3 with intact UIMs (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Pathogenic ataxin-3 interacts with Hsc70-4 in a UIM-dependent manner.</title><p>(<bold>A</bold>) SDS-PAGE gel stained for all proteins with Sypro Ruby. Boxed areas were excised and proteins were identified with LC/MS/MS. Two versions of immunopurifications (IPs) were conducted. Middle panel shows results from IP-ed ataxin-3 from whole fly lysates. Right panel shows results from IP-ed ataxin-3 after lysates were first incubated with tandem ubiquitin binding entities (TUBEs; see the main text and Materials and methods). (<bold>B–D</bold>) Western blots from anti-HA IPs from flies. Results are representative of independent biological replicates conducted three times. NS: non-specific.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Data related to <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60742-fig5-data1-v1.pdf.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig5-v1.tif"/></fig><p>We confirmed mass spectrometry data with co-IPs. Full-length, pathogenic ataxin-3 co-IP-ed endogenous Hsc70-4 in a UIM-dependent manner: whereas pathogenic ataxin-3 with intact UIMs co-IP-ed Hsc70-4, we did not observe the same with UIM-mutated, pathogenic ataxin-3 (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The interaction of ataxin-3 with Hsc70-4 could potentially rely more heavily on UIM3. We inferred this from IPs with isolated polyQ peptides. PolyQ80-UIM3 co-IP-ed endogenous Hsc70-4 more readily than polyQ80 alone or polyQ80 with UIMs 1 and 2 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). In panel 5D, we conducted co-IPs with modified conditions to approximate more the levels of the HA-tagged polyQ forms. All three polyQ80 versions co-IP-ed Hsc70-4, but UIM3 appeared more important than the two other UIMs in facilitating an interaction. Collectively, these results highlight the UIMs of ataxin-3 as an interaction site for Hsc70-4 in vivo.</p></sec><sec id="s2-5"><title>Hsc70-4 enhances aggregation and toxicity of pathogenic ataxin-3</title><p>Hsc70-4 belongs to the heat shock protein 70 (HSP70) superfamily. Its closest human ortholog is the constitutively expressed, heat shock protein family A member 8 (HSPA8; <xref ref-type="bibr" rid="bib73">Takayama et al., 1999</xref>). Alongside other HSP70 members, its primary role is that of an ATP-dependent chaperone for unfolded proteins in protein quality control (<xref ref-type="bibr" rid="bib88">Yamamoto et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Grove et al., 2011</xref>; <xref ref-type="bibr" rid="bib27">Goodwin et al., 2014</xref>; <xref ref-type="bibr" rid="bib41">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">Sopha et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Robert et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Loeffler, 2019</xref>; <xref ref-type="bibr" rid="bib1">Abildgaard et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Davis et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Faust and Rosenzweig, 2020</xref>). HSPA8 is a part of the ubiquitin-proteasome degradation system and is also involved in chaperone-mediated autophagy (<xref ref-type="bibr" rid="bib61">Robert et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Loeffler, 2019</xref>; <xref ref-type="bibr" rid="bib70">Stricher et al., 2013</xref>; <xref ref-type="bibr" rid="bib36">Kampinga and Bergink, 2016</xref>). Chaperones are presumed to alleviate toxicity from polyQ proteins by refolding or degrading them. Our studies, however, counterintuitively hint at the possibility that Hsc70-4 might do the opposite with ataxin-3, enhancing its polyQ toxicity.</p><p>Hsc70-4 is a different member of the HSP70 superfamily than fly Hsc70Cb and human HSPA1L, both of which were previously reported to suppress polyQ-dependent degeneration (<xref ref-type="bibr" rid="bib85">Warrick et al., 1999</xref>; <xref ref-type="bibr" rid="bib89">Zhang et al., 2010</xref>; <xref ref-type="bibr" rid="bib32">Iijima-Ando et al., 2005</xref>; <xref ref-type="bibr" rid="bib14">Chan et al., 2002</xref>). Also, there is recent evidence that HSP70 members have pleiotropic effects on misfolded proteins (<xref ref-type="bibr" rid="bib64">Serlidaki et al., 2020</xref>). Therefore, we knocked down Hsc70-4 in fly eyes to examine the possibility that it exacerbates SCA3. We selected fly eyes because widespread targeting of Hsc70-4 in the fly was developmentally lethal (larval, pupal, and pharate adult lethality), whereas expression in fly eyes was not problematic (clearly present pseudopupil and good overall morphology). We utilized three independent RNAi lines for Hsc70-4. Expression of each line in fly eyes led to reduced Hsc70-4 levels (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Levels of Hsc70-4 in fly eyes were likely even lower than what was captured by blots; we expressed RNAi in eyes but conducted blotting using whole heads that also contained tissues where Hsc70-4 was not targeted.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Hsc70-4 knockdown improves ataxin-3 toxicity in fly eyes.</title><p>(<bold>A</bold>) Western blots from dissected fly heads. Histograms are from blots on top and other, independent biological repeats. Shown are means -/+ SD. Statistics: one-way ANOVA with Dunnett's correction. Lysates were from crosses used for studies in panels (<bold>B</bold>), (<bold>C</bold>) and other, similar experimental setups. (<bold>B</bold>) Representative images and summary of the scoring system designed to evaluate the effect of Hsc70-4 knockdown on the phenotype caused by pathogenic ataxin-3 in fly eyes. 1: normal-looking eyes that have a clearly defined pseudopupil and good overall appearance; 2: eyes where the pseudopupil is not as clearly pronounced compared with normal eyes and with some minor unevenness/irregularity in peripheral bristle arrangement; 3: eyes where the pseudopupil is not visible; 4: eyes with depigmentation. Quantitative outcomes are shown in panels (<bold>C</bold>) intact, pathogenic ataxin-3 and (<bold>F</bold>) UIM-mutated, pathogenic ataxin-3. (<bold>C</bold>) Statistics: Kruskal-Wallis tests comparing Hsc70-4 RNAi to Ctrl from independent biological replicates when pathogenic ataxin-3 is expressed in fly eyes. Shown are means -/+ SEM. (<bold>D</bold>) Western blots from dissected fly heads. Quantifications are from panels above and independent biological repeats. Shown are means -/+ SD. P values: one-way ANOVA with Dunnett's correction. Black arrow: unmodified ataxin-3. Red arrow: potentially phosphorylated species that we observe infrequently. Blue arrows: ubiquitinated ataxin-3. (<bold>E</bold>) Filter-trap assays. P values: one-way ANOVA with Dunnett's correction. Shown are means -/+ SD. Images are from the same membrane, cropped and reorganized for clarity. Full lane is in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>. (<bold>F</bold>) Quantification of eye scores as in panels (<bold>B</bold>) and (<bold>C</bold>). Shown are means -/+ SEM. ‘N's signify biological replicates. Italicized P values are not statistically significant. For panels (<bold>C</bold>) and (<bold>F</bold>), the numbers at the bottom of each histogram show the number of flies in each scoring category for that group.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Data related to <xref ref-type="fig" rid="fig6">Figure 6</xref> - part 1.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-60742-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Data related to <xref ref-type="fig" rid="fig6">Figure 6</xref> - part 2.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60742-fig6-data2-v1.pdf.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Uncropped blot from panel 6E.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig6-figsupp1-v1.tif"/></fig></fig-group><p>Next, we determined the effect of knocking down Hsc70-4 on the phenotype caused by pathogenic ataxin-3 by scoring fly eyes, as exemplified in <xref ref-type="fig" rid="fig6">Figure 6B</xref>; a higher number denotes a worse phenotype. Hsc70-4 knockdown consistently improved eye phenotype, denoted by the persistence of the pseudopupil − an indicator of underlying structure integrity − and fewer cases with depigmentation (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). We also observed biochemical changes in ataxin-3 when Hsc70-4 was knocked down. Both SDS-resistant ataxin-3 species and aggregates isolated by filter-trap assays were reduced in the presence of Hsc70-4 RNAi (<xref ref-type="fig" rid="fig6">Figure 6D,E</xref>). Since aggregation of ataxin-3 is a key determinant of its toxicity in flies (<xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>), suppression of eye phenotypes by Hsc70-4 knockdown is likely a consequence of reduced SCA3 protein aggregation. Lastly, we tested the effect of Hsc70-4 knockdown on eye phenotypes from ataxin-3 with mutated UIMs. Knocking down Hsc70-4 did not have a detectable impact on eye phenotype caused by pathogenic ataxin-3(UIM*) (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Collectively, these data highlight Hsc70-4 as an enhancer of pathogenic ataxin-3 toxicity in a manner dependent on UIMs.</p></sec><sec id="s2-6"><title>Hsc70-4 knockdown suppresses polyQ toxicity more generally</title><p>We were intrigued by the suppressive effect of Hsc70-4 knockdown on pathogenic ataxin-3. Because we also observed Hsc70-4 co-IP with the isolated polyQ (<xref ref-type="fig" rid="fig5">Figure 5C,D</xref>) we tested whether its knockdown impacts polyQ80 eye phenotypes. Expression of polyQ80 led to pseudopupil loss and depigmentation. Knockdown of Hsc70-4 improved depigmentation, even though it did not recover the pseudopupil, indicative of ameliorated pathology (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Importantly, improved eye phenotype was accompanied by reduced polyQ80 aggregates (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). (We note here that we have not observed a single, non-aggregated band of polyQ80 by western blots; we only observed aggregated species.)</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Hsc70-4 knockdown improves toxicity from independent, truncated polyQ models.</title><p>Representative images of fly eyes (<bold>A, C</bold>) and fly eye sections (<bold>C</bold>) with the noted genotypes. Photos are representative of results from three independent sets of crosses. (<bold>B</bold>) Western blots from dissected heads. Results from two independent biological repeats are shown. ‘Ctrl’ in blue font did not express polyQ80. NS: non-specific.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Data related to <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60742-fig7-data1-v1.pdf.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig7-v1.tif"/></fig><p>We confirmed a protective effect from Hsc70-4 knockdown in yet another polyQ model (<xref ref-type="bibr" rid="bib84">Warrick et al., 1998</xref>). This model contains polyQ78 and the C-terminus of an ataxin-3 isoform that lacks UIM3; UIMs 1 and 2 are also absent. Because expression of this polyQ species does not always yield a clear external eye phenotype, we examined internal structures. Normally, the ommatidia (eye units) are organized in a fan-like pattern, which was absent in the presence of polyQ78 (ATXN3<sup>TR</sup>-Q78; <xref ref-type="fig" rid="fig7">Figure 7C</xref>). When Hsc70-4 was knocked down, the ommatidia were visible in a clear sign of toxicity suppression. Altogether, these results suggest the possibility of a wider role for Hsc70-4 as an enhancer of toxicity from different polyQ proteins.</p></sec><sec id="s2-7"><title>UIMs are important for inter-ataxin-3 interactions</title><p>So far, we observed that Hsc70-4 affects aggregation and toxicity of pathogenic ataxin-3 and that it interacts with the SCA3 protein through UIMs (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>). Since our data also implicated Hsc70-4 in the toxicity of an isolated polyQ that does not contain UIMs (<xref ref-type="fig" rid="fig7">Figure 7</xref>) we wondered whether the UIMs of ataxin-3 have additional properties that might impact SCA3 protein aggregation.</p><p>Ataxin-3 proteins bind each other (<xref ref-type="bibr" rid="bib21">Ellisdon et al., 2006</xref>; <xref ref-type="bibr" rid="bib75">Todi et al., 2007a</xref>; <xref ref-type="bibr" rid="bib49">Masino et al., 2004</xref>; <xref ref-type="bibr" rid="bib50">Masino et al., 2011</xref>). Therefore, we investigated whether the UIMs play a part in inter-ataxin-3 associations. We examined whether HA-tagged, pathogenic ataxin-3 with intact or mutated UIMs co-IPs V5-tagged pathogenic ataxin-3 with intact UIMs in <italic>Drosophila</italic>. We found that the UIMs were important, but not necessary, for these interactions; a reduced amount of full-length, V5-tagged pathogenic ataxin-3 co-IP-ed with UIM* ataxin-3 compared to ataxin-3 with intact UIMs (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Additional co-IPs using truncated polyQ fragments and ataxin-3 with a wild-type polyQ indicated that UIM3 is more important for this interaction than UIMs 1 and 2 (<xref ref-type="fig" rid="fig8">Figure 8B</xref>) and suggested that the UIMs are involved not only in the interaction of disease-causing ataxin-3, but also in the unexpanded version. It is not unexpected that the UIMs are not essential for ataxin-3 interactions; in vitro experiments showed that the N-terminal Josephin domain facilitates inter-ataxin-3 associations (<xref ref-type="bibr" rid="bib21">Ellisdon et al., 2006</xref>; <xref ref-type="bibr" rid="bib49">Masino et al., 2004</xref>; <xref ref-type="bibr" rid="bib50">Masino et al., 2011</xref>). Thus, the UIMs of ataxin-3 enable inter-ataxin-3 interactions, which might additionally contribute to aggregation and toxicity in SCA3.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>UIMs are important for inter-ataxin-3 interactions.</title><p>(<bold>A, B</bold>) Western blots from IPs of ataxin-3 with expanded (<bold>A</bold>) or wild-type (<bold>B</bold>) polyQ repeats expressed in fly eyes. All transgenes (HA- or V5-tagged) were expressed at the same time and in the same tissues. Gray arrow: V5-positive signal absent in IP lanes. Red arrows: likely proteolytic fragments. Black arrows: unmodified proteins. Blue arrows: ubiquitinated ataxin-3. NS: non-specific. Images are representative of independent biological experiments conducted thrice.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Data related to <xref ref-type="fig" rid="fig8">Figure 8B</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-60742-fig8-data1-v1.pdf.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig8-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we systematically explored the role of protein context in SCA3 in an intact organism. We found that the UIMs of ataxin-3 are key players in pathogenicity through an unexpected role from Hsc70-4, which exacerbates SCA3. We propose that Hsc70-4 increases the toxicity of pathogenic ataxin-3 by interacting with its UIMs and worsening polyQ aggregation (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). Additionally, since the UIMs facilitate inter-ataxin-3 binding, misfolded ataxin-3 proteins may be brought into close proximity that can further increase their chances of interaction, aggregation and toxicity (<xref ref-type="fig" rid="fig9">Figure 9A</xref>); as mentioned earlier, in our <italic>Drosophila</italic> studies of SCA3, ataxin-3 aggregation is consistently linked to its extent of pathogenicity. Our work provides the first, comprehensive view of the role of non-polyQ domains on ataxin-3 toxicity (<xref ref-type="fig" rid="fig9">Figure 9</xref>); it furthermore highlights an understudied and impactful property of a member of the normally beneficial HSP70 superfamily.</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Proposed model.</title><p>(<bold>A</bold>) Ataxin-3 UIMs enable its interaction with Hsc70-4 and other ataxin-3 proteins, both of which enhance aggregation and toxicity. UIM3 (thicker lines) appears to be a stronger contributor to these interactions than the other UIMs (thinner lines). (<bold>B</bold>) Summary of results from the current study and our prior publications on the effect of ataxin-3 domains on its polyQ toxicity (<xref ref-type="bibr" rid="bib8">Blount et al., 2014</xref>; <xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>). Ub: ubiquitin.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig9-v1.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Relative importance of UIMs on fly longevity.</title><p>(<bold>A</bold>) Longevity curves of adult flies expressing the denoted transgenes pan-neuronally. Continuous curves are the same as in <xref ref-type="fig" rid="fig1">Figure 1C</xref>; X-axis is extended to 86 days to show the full longevity of control flies. Blue dots are ‘approximated longevity’ of flies expressing pathogenic ataxin-3 with mutated UIMs, based on data from <xref ref-type="fig" rid="fig3">Figure 3C</xref>. The UIM* flies are isogenic to the polyQ truncation transgenes and the full-length ataxin-3 transgene used in <xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig8">8</xref>; therefore, the UIM* flies cannot be directly compared to the lines used for <xref ref-type="fig" rid="fig1">Figure 1</xref>, since the Kozak sequence is different; also, the polyQ is encoded by a 'CAGCAA' repeat for flies used in <xref ref-type="fig" rid="fig2">Figures 2</xref>–<xref ref-type="fig" rid="fig8">8</xref>, compared to a pure 'CAG' for flies in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Lines in <xref ref-type="fig" rid="fig1">Figure 1</xref> are all isogenic to each-other. Calculations for the rough estimation are on the table on the right. (<bold>B</bold>) Another measure of improvement in fly longevity when the VBM or the UIMs are mutated, compared to their respective, isogenic ‘Intact’ controls. Columns D and G show percent improvement in longevity for flies expressing VBM-mutated ataxin-3 compared to their own isogenic ‘Intact’ (column D; data from <xref ref-type="fig" rid="fig1">Figure 1</xref>) and flies expressing UIM-mutated ataxin-3 compared to their own isogenic ‘Intact’ (column G; data from <xref ref-type="fig" rid="fig3">Figure 3</xref>). Green font indicates that UIM* flies showed more improvement than VBM* ones.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-60742-fig9-figsupp1-v1.tif"/></fig></fig-group><p>We previously reported on the role of three ataxin-3 domains on its polyQ toxicity: the catalytic domain, UbS2, and the VBM (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). Based on our work in <italic>Drosophila</italic>, the catalytic domain is important for ataxin-3's ability to induce production of the co-chaperone, DnaJ-1, whose upregulation suppresses polyQ toxicity (<xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>). The capacity of ataxin-3 to upregulate DnaJ-1 also requires its binding to the proteasome-associated protein, Rad23 at UbS2 (<xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>). Through upregulated DnaJ-1, ataxin-3 suppresses its own polyQ-dependent toxicity (<xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib79">Tsou et al., 2013</xref>). Therefore, it is not surprising that mutating either the catalytic site or UbS2 on pathogenic ataxin-3 renders the protein more toxic. The general suppressive contribution of each domain to ataxin-3 polyQ toxicity, as measured by longevity, is similar.</p><p>Unlike the catalytic site and UbS2, the other domains investigated − VBM and UIMs − act as enhancers of ataxin-3 polyQ toxicity. Elegant work by the Wanker and Bonini labs identified a region immediately preceding the polyQ of ataxin-3 as the binding site for VCP (<xref ref-type="bibr" rid="bib10">Boeddrich et al., 2006</xref>; <xref ref-type="fig" rid="fig9">Figure 9B</xref>). The stoichiometry of this interaction was suggested to be four ataxin-3 proteins for one VCP hexamer (<xref ref-type="bibr" rid="bib10">Boeddrich et al., 2006</xref>). These results and our findings that VCP binding enhances ataxin-3 aggregation and toxicity (<xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>) led us to propose that the interaction of multiple ataxin-3 proteins with a single VCP hexamer increases their chances of interaction and accelerates aggregation (<xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="fig" rid="fig9">Figure 9B</xref>). The other domains that enhance the toxicity of ataxin-3 are the UIMs. Their relative impact on ataxin-3 polyQ toxicity might be stronger than the VBM (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref>). Our results strongly implicate Hsc70-4 as a driving force behind the role of the UIMs as enhancers of ataxin-3 pathogenicity.</p><p>It is intriguing that knockdown of Hsc70-4 reduces toxicity from pathogenic ataxin-3. As mentioned above, heat shock proteins generally work to improve toxicity from aggregated proteins (<xref ref-type="bibr" rid="bib17">Davis et al., 2020</xref>; <xref ref-type="bibr" rid="bib85">Warrick et al., 1999</xref>; <xref ref-type="bibr" rid="bib20">Duncan et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Evans et al., 2010</xref>; <xref ref-type="bibr" rid="bib74">Thiruvalluvan et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Chan et al., 2000</xref>; <xref ref-type="bibr" rid="bib83">Vossfeldt et al., 2012</xref>; <xref ref-type="bibr" rid="bib36">Kampinga and Bergink, 2016</xref>). Hsc70-4 may act in a context-, protein-, and disease-dependent manner. For example, studies with its mammalian ortholog, HSPA8, indicate that it can suppress aggregation and toxicity of the HD-causing protein, huntingtin, harboring an expanded polyQ (<xref ref-type="bibr" rid="bib63">Scior et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Monsellier et al., 2015</xref>; <xref ref-type="bibr" rid="bib4">Bauer et al., 2010</xref>). However, investigations with the disease-causing protein, Tau, suggest this chaperone as a potential enhancer of tauopathies. HSPA8 interacts with Tau and slows down its degradation; also, HSPA8 inhibition can reduce Tau levels in the brain (<xref ref-type="bibr" rid="bib25">Fontaine et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Jinwal et al., 2009</xref>; <xref ref-type="bibr" rid="bib34">Jinwal et al., 2013</xref>). These data present the possibility of HSPA8 activities that can lead to enhanced toxicity from some proteins, similar to what we observed with ataxin-3.</p><p>How might Hsc70-4 enhance toxicity from pathogenic ataxin-3? Perhaps, ATP hydrolysis by Hsc70-4 is directly inhibited by binding to the UIMs of pathogenic ataxin-3, abrogating its refolding functions. It may also be that under normal circumstances ataxin-3 forms a functional complex with Hsc70-4, collaborating in protein quality control. Just like Hsc70-4/HSPA8, wild-type ataxin-3 is implicated in proteostasis (<xref ref-type="bibr" rid="bib15">Costa and Paulson, 2012</xref>; <xref ref-type="bibr" rid="bib16">Dantuma and Herzog, 2020</xref>). During normal conditions, a complex comprising wild-type ataxin-3, Hsc70-4 and other proteins could triage various substrates. When the polyQ of ataxin-3 is expanded, in a UIM-dependent manner, it may cause Hsc70-4 to adopt a dominant negative role and to enhance pathogenic ataxin-3 aggregation. Our study provides a roadmap toward testing these possibilities and uncovering others.</p><p>The model above focuses on the role of the UIMs facilitating an interaction between ataxin-3 and Hsc70-4, because pathogenic ataxin-3 with mutated UIMs does not co-IP Hsc70-4. However, we also observed that the isolated polyQ80 co-IP-ed some Hsc70-4 and that the chaperone’s knockdown reduced its toxicity. Two earlier studies also reported the suppression of truncated polyQ toxicity by the knockdown of Hsc70-4 in flies (<xref ref-type="bibr" rid="bib89">Zhang et al., 2010</xref>; <xref ref-type="bibr" rid="bib83">Vossfeldt et al., 2012</xref>). (To the best of our knowledge, no additional findings have supplemented these data since their original publication.) Binding of Hsc70-4 to an isolated polyQ is not surprising. PolyQ peptides aggregate and heat shock proteins interact with misfolded proteins (<xref ref-type="bibr" rid="bib20">Duncan et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Evans et al., 2010</xref>; <xref ref-type="bibr" rid="bib36">Kampinga and Bergink, 2016</xref>). However, it is compelling that reducing levels of Hsc70-4 improves, instead of worsening, truncated polyQ toxicity. Other proteins involved with refolding, such as the HSP40 members Dnaj and mrj, and the HSP70 members Hsc70Cb and HSPA1L reduce polyQ protein aggregation and toxicity (<xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib81">Tsou et al., 2015b</xref>; <xref ref-type="bibr" rid="bib85">Warrick et al., 1999</xref>; <xref ref-type="bibr" rid="bib89">Zhang et al., 2010</xref>; <xref ref-type="bibr" rid="bib13">Chan et al., 2000</xref>; <xref ref-type="bibr" rid="bib7">Bilen and Bonini, 2007</xref>). But these proteins are not the same as Hsc70-4/HSPA8, which may function differently depending on protein identity and cellular circumstances. In fact, HSPA8 is not the only member of the HSP70 superfamily to enhance the aggregation of a misfolded disease protein. Recent work in cultured mammalian cells indicated that HSPA1L − previously reported as a polyQ suppressor (<xref ref-type="bibr" rid="bib85">Warrick et al., 1999</xref>; <xref ref-type="bibr" rid="bib32">Iijima-Ando et al., 2005</xref>; <xref ref-type="bibr" rid="bib14">Chan et al., 2002</xref>) − can in fact increase the aggregation of a non-polyQ misfolded protein, SOD1; the mechanism behind this effect is not entirely clear but it appears to involve HSPA1L binding partners (<xref ref-type="bibr" rid="bib64">Serlidaki et al., 2020</xref>). Consequently, it is not outside of reasonable biological expectations that not all HSP70 members, such as Hsc70-4, function similarly; they may trigger different outcomes on misfolded proteins depending on their binding partners, the identity of the misfolded protein, the cellular environment and physiological conditions.</p><p>How might Hsc70-4 worsen polyQ fragment toxicity? The interaction of Hsc70-4 with severely truncated polyQ peptides could inhibit its ability to refold them, especially if additional proteins or binding partners are necessary to steer Hsc70-4 toward refolding, as suggested by studies of other HSP70 members (<xref ref-type="bibr" rid="bib64">Serlidaki et al., 2020</xref>). This point pertains to isolated polyQ fragments. In the case of full-length ataxin-3, the UIMs’ interaction with Hsc70-4 appears stronger and likely supersedes binding through the polyQ, leading to the models of aggregation postulated above. We draw this conclusion based on our results that mutating the UIMs of full-length, pathogenic ataxin-3 seems to abrogate its interaction with endogenous Hsc70-4. Additionally, knockdown of Hsc70-4 does not significantly change eye phenotype scores when the UIMs of full-length ataxin-3 are mutated. Nevertheless, we cannot fully discount the possibility that Hsc70-4 activities on the SCA3 protein may also depend on polyQ-based interactions, once UIM-based binding is established. At this point, the primary takeaway is that Hsc70-4 can enhance polyQ toxicity, in the case of ataxin-3 through its UIMs.</p><p>In summary, we demonstrated that non-polyQ domains of disease-causing ataxin-3 are key regulators of its toxicity, and that the UIMs are important determinants of the SCA3 protein's pathogenicity. Our studies establish a clear role for protein context in SCA3 and, through Hsc70-4, provide a unique entry point into further examinations and potential therapeutic solutions for this incurable ataxia. Lastly, our findings that Hsc70-4 can enhance polyQ toxicity have broader implications for the general understanding of chaperone biology.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Antibodies</title><p>Anti-ataxin-3 (mouse monoclonal 1H9, MAB5360, 1:500–1000; Millipore), anti-MJD (rabbit polyclonal, 1:15,000 <xref ref-type="bibr" rid="bib58">Paulson et al., 1997</xref>), anti-HA (rabbit monoclonal C29F4, 1:500–1000; Cell Signaling Technology), anti-V5 (mouse monoclonal R960-25, 1:500–1000; ThermoFisher), anti-tubulin (mouse monoclonal T5168, 1:10,000; Sigma-Aldrich), anti-lamin (mouse monoclonal ADL84.12–5, 1:1000; Developmental Studies Hybridoma Bank), anti-HSPA8/Hsc70-4 (rabbit monoclonal D12F2, 1:1000; Cell Signaling Technology), peroxidase conjugated secondary antibodies (goat anti-mouse, goat anti-rabbit, 1:5000–10,000; Jackson Immunoresearch).</p></sec><sec id="s4-2"><title><italic>Drosophila</italic> materials and procedures</title><p>Flies were housed at 25°C in diurnal environments on conventional cornmeal or RU486-containing media. Common stocks were from Bloomington <italic>Drosophila</italic> Stock Center: GMR-Gal4 (#8121); isogenic host strain attP2 (#36303); Hsc70-4 RNAi lines #1, 2, and 3 (#28709, #34836, and #35684, respectively), GMR-QF2W (#59283), and ATXN3<sup>TR</sup>-Q78 (#8141). Gifts included: sqh-Gal4 (Dr. Daniel Kiehart, Duke University), elav-GS-Gal4 (Dr. R. J. Wessells, Wayne State University), elav-Gal4 and repo-Gal4 (Dr. Daniel Eberl, University of Iowa). All flies were heterozygous for driver and transgene.</p><p>Ataxin-3 cDNAs were based on sequences from previous publications (<xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>; <xref ref-type="bibr" rid="bib31">Harris et al., 2010</xref>; <xref ref-type="bibr" rid="bib87">Winborn et al., 2008</xref>; <xref ref-type="bibr" rid="bib77">Todi et al., 2009</xref>; <xref ref-type="bibr" rid="bib55">Nicastro et al., 2010</xref>; <xref ref-type="bibr" rid="bib5">Berke et al., 2005</xref>; <xref ref-type="bibr" rid="bib54">Nicastro et al., 2009</xref>). These include ataxin-3(SCA3): -intact, -catalytically inactive, -UbS2 mutated, -VBM mutated; as well as isolated polyQ80, UIM1-2-Q80, Q80-UIM3, UIM1-2-Q80-UIM3, and ataxin-3(SCA3)-UIMs mutated. Transgenes were sub-cloned into pWalium-10.moe. Transgenic lines were generated via phiC31 integration into attP2 on chromosome 3 (<xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>; <xref ref-type="bibr" rid="bib82">Tsou et al., 2016</xref>). An additional ataxin-3 line was generated for <xref ref-type="fig" rid="fig8">Figure 8</xref> with the same sequence as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>, but with a V5 tag, using plasmid pQUASp (Addgene #46162) and driven by GMR-QF2W. All transgene insertions were validated by PCR and genomic sequencing and western blotting, using procedures described before (<xref ref-type="bibr" rid="bib60">Ristic et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Sutton et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Tsou et al., 2015a</xref>; <xref ref-type="bibr" rid="bib35">Johnson et al., 2019</xref>; <xref ref-type="bibr" rid="bib82">Tsou et al., 2016</xref>; <xref ref-type="bibr" rid="bib9">Blount et al., 2018</xref>).</p><p>For longevity and motility, adults were collected on the day of eclosion. Deaths were recorded daily. Motility was tested weekly. For motility, adults were transferred into fresh vials 1 hr before assessment. Then, the percentage of flies per vial to reach the top at 5, 15, and 30 s was recorded after flies were forced to the bottom.</p></sec><sec id="s4-3"><title>Western blotting and quantification</title><p>Unless otherwise specified, 3 or 5 flies (depending on experiment), or 10 dissected adult heads per group were homogenized in boiling lysis buffer (50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 100 mM dithiothreitol), sonicated, boiled for 10 min, and centrifuged at 13,300xg at room temperature for 10 min. Western blots were developed using PXi 4 (Syngene), or ChemiDoc (Bio-Rad). Blots were quantified with GeneSys (Syngene), or ImageLab (Bio-Rad), respectively. For direct blue staining, PVDF membranes were submerged for 10 min in 0.008% Direct Blue 71 (Sigma-Aldrich) in 40% ethanol and 10% acetic acid, rinsed in 40% ethanol/10% acetic acid, air dried, and imaged.</p></sec><sec id="s4-4"><title>Filter-trap assay</title><p>Three adult flies, or 10 dissected heads per group were homogenized in 200 μL NETN buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40) supplemented with protease inhibitor cocktail (PI; S-8820, Sigma-Aldrich). Lysates were diluted with 200 μL PBS containing 0.5% SDS, sonicated briefly, then centrifuged at 4500×g for 1 min. 100 μL supernatant was diluted with 400 μL PBS. Thirty or 70 μL (depending on experimental setup) of each sample was filtered-vacuumed using Bio-Dot (Bio-Rad) through a 0.45 μm nitrocellulose membrane (Schleicher and Schuell) that was pre-incubated with 0.1% SDS in PBS. Membrane was rinsed twice with 0.1% SDS/PBS and analyzed by western blotting.</p></sec><sec id="s4-5"><title>Soluble/pellet centrifugation</title><p>Ten whole flies per group were lysed in 300 μL NETN buffer with PI, sonicated, then centrifuged at 20,000×g at 4°C for 30 min. Supernatant was quantified with the BCA assay (ThermoFisher). Pellet was resuspended in 200 μL of PBS/1% SDS. Thirty μg of supernatant fraction and 7 μL of resuspended pellet was each supplemented with 6× SDS, boiled, and loaded for western blotting.</p></sec><sec id="s4-6"><title>Nuclear/cytoplasmic separation</title><p>Fractionation was performed using the ReadyPrep Protein Extraction Kit (Bio-Rad) using five whole flies per group that were lysed in cytoplasmic extraction buffer (Bio-Rad). Three times as much nuclear fraction was loaded onto gels compared to cytoplasmic fraction to eliminate the need for over-exposure.</p></sec><sec id="s4-7"><title>Co-immunopurifications</title><p>Fifteen whole flies or 5-30 dissected fly heads per group, depending on experiment, were lysed in NETN+PI, tumbled at 4°C for 30 min, then centrifuged for 5 min at 10,000×g at 4°C. Supernatant was incubated with bead-bound antibody for 2–4 hr. Then, beads were rinsed 5× with NETN+PI. Bead-bound complexes were eluted by boiling in Laemmli buffer.</p></sec><sec id="s4-8"><title>Mass spectrometry</title><p>Forty whole flies per group were homogenized in 1 mL NETN+PI, sonicated, centrifuged at 4°C for 5 min at 10,000×g and supernatant was transferred into a fresh microfuge tube. Half of each sample was incubated with anti-HA beads (ThermoFisher) for 2 hr, rinsed 4× with NETN and bead-bound proteins were eluted with Laemmli buffer. The other half was tumbled for 30 min with an equal mixture of tandem ubiquitin binding entities (TUBEs) 1 and 2 (Lifesensors), centrifuged to isolate TUBE beads and the supernatant was incubated for 2 hr with anti-HA beads, rinsed and eluted as above. Eluates were resolved on an SDS-PAGE gel that was stained with Sypro Ruby (ThermoFisher). Bands of interest were excised and examined by LC/MS/MS at Wayne State University Mass Spectrometry Core.</p></sec><sec id="s4-9"><title>Histological preparation</title><p>The proboscises and wings of adult flies were removed before fixing overnight in 2% glutaraldehyde/2% paraformaldehyde in Tris-buffered saline/0.1% Triton X-100. Fixed bodies were dehydrated in a series of 30, 50, 70, and 100% ethanol for 1 hr each, washed in propylene oxide overnight, embedded in Poly/Bed812 (Polysciences), sectioned at 5 μm, and stained with toluidine blue.</p></sec><sec id="s4-10"><title>Statistical analyses</title><p>Statistical tests are specified in figure legends. Log-rank tests with Holm-Bonferroni adjustments, ANOVA, and Kruskal-Wallis tests were conducted in Prism 8 (GraphPad); Student's t-tests were conducted in Excel (Microsoft) or Numbers (Apple). P values are noted as reported by the software used. The number of biological replicates is noted on figures and corresponding legends. We have also noted in legends whether two-tailed or one-tailed tests were used. Two-tailed tests were used where a directionality of change was not necessarily predicted. One-tailed tests were used where a specific directionality in change between control and experimental groups was expected. In figures, non-statistically significant outcomes are noted in italicized font, whereas statistically significant outcomes are in normal font.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Matt Scaglione (Duke University) for critical input. We also thank Jamie Roebuck (Duke University Model System Genomics) for the generation of transgenic fly lines, and Madeline Somers (University of Michigan) for statistical consulting.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Validation, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Data curation, Software, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-60742-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>No large-scale datasets were generated or analyzed for this study. All results pertaining to the figures and the text are included in figures and supplementary files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abildgaard</surname> <given-names>AB</given-names></name><name><surname>Gersing</surname> <given-names>SK</given-names></name><name><surname>Larsen-Ledet</surname> <given-names>S</given-names></name><name><surname>Nielsen</surname> <given-names>SV</given-names></name><name><surname>Stein</surname> <given-names>A</given-names></name><name><surname>Lindorff-Larsen</surname> <given-names>K</given-names></name><name><surname>Hartmann-Petersen</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Co-Chaperones in targeting and delivery of misfolded proteins to the 26S proteasome</article-title><source>Biomolecules</source><volume>10</volume><elocation-id>1141</elocation-id><pub-id pub-id-type="doi">10.3390/biom10081141</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname> <given-names>KM</given-names></name><name><surname>Hofmann</surname> <given-names>K</given-names></name><name><surname>Hartmann-Petersen</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Ubiquitin-binding proteins: similar, but different</article-title><source>Essays in Biochemistry</source><volume>41</volume><fpage>49</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1042/EB0410049</pub-id><pub-id pub-id-type="pmid">16250897</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bañez-Coronel</surname> <given-names>M</given-names></name><name><surname>Ayhan</surname> <given-names>F</given-names></name><name><surname>Tarabochia</surname> <given-names>AD</given-names></name><name><surname>Zu</surname> <given-names>T</given-names></name><name><surname>Perez</surname> <given-names>BA</given-names></name><name><surname>Tusi</surname> <given-names>SK</given-names></name><name><surname>Pletnikova</surname> <given-names>O</given-names></name><name><surname>Borchelt</surname> <given-names>DR</given-names></name><name><surname>Ross</surname> <given-names>CA</given-names></name><name><surname>Margolis</surname> <given-names>RL</given-names></name><name><surname>Yachnis</surname> <given-names>AT</given-names></name><name><surname>Troncoso</surname> <given-names>JC</given-names></name><name><surname>Ranum</surname> <given-names>LP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RAN translation in Huntington disease</article-title><source>Neuron</source><volume>88</volume><fpage>667</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.10.038</pub-id><pub-id pub-id-type="pmid">26590344</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname> <given-names>PO</given-names></name><name><surname>Goswami</surname> <given-names>A</given-names></name><name><surname>Wong</surname> <given-names>HK</given-names></name><name><surname>Okuno</surname> <given-names>M</given-names></name><name><surname>Kurosawa</surname> <given-names>M</given-names></name><name><surname>Yamada</surname> <given-names>M</given-names></name><name><surname>Miyazaki</surname> <given-names>H</given-names></name><name><surname>Matsumoto</surname> <given-names>G</given-names></name><name><surname>Kino</surname> <given-names>Y</given-names></name><name><surname>Nagai</surname> <given-names>Y</given-names></name><name><surname>Nukina</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein</article-title><source>Nature Biotechnology</source><volume>28</volume><fpage>256</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1038/nbt.1608</pub-id><pub-id pub-id-type="pmid">20190739</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berke</surname> <given-names>SJ</given-names></name><name><surname>Chai</surname> <given-names>Y</given-names></name><name><surname>Marrs</surname> <given-names>GL</given-names></name><name><surname>Wen</surname> <given-names>H</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>32026</fpage><lpage>32034</lpage><pub-id pub-id-type="doi">10.1074/jbc.M506084200</pub-id><pub-id pub-id-type="pmid">16040601</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bichelmeier</surname> <given-names>U</given-names></name><name><surname>Schmidt</surname> <given-names>T</given-names></name><name><surname>Hübener</surname> <given-names>J</given-names></name><name><surname>Boy</surname> <given-names>J</given-names></name><name><surname>Rüttiger</surname> <given-names>L</given-names></name><name><surname>Häbig</surname> <given-names>K</given-names></name><name><surname>Poths</surname> <given-names>S</given-names></name><name><surname>Bonin</surname> <given-names>M</given-names></name><name><surname>Knipper</surname> <given-names>M</given-names></name><name><surname>Schmidt</surname> <given-names>WJ</given-names></name><name><surname>Wilbertz</surname> <given-names>J</given-names></name><name><surname>Wolburg</surname> <given-names>H</given-names></name><name><surname>Laccone</surname> <given-names>F</given-names></name><name><surname>Riess</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence</article-title><source>Journal of Neuroscience</source><volume>27</volume><fpage>7418</fpage><lpage>7428</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4540-06.2007</pub-id><pub-id pub-id-type="pmid">17626202</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilen</surname> <given-names>J</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Genome-Wide screen for modifiers of Ataxin-3 neurodegeneration in <italic>Drosophila</italic></article-title><source>PLOS Genetics</source><volume>3</volume><elocation-id>e177</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.0030177</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blount</surname> <given-names>JR</given-names></name><name><surname>Tsou</surname> <given-names>WL</given-names></name><name><surname>Ristic</surname> <given-names>G</given-names></name><name><surname>Burr</surname> <given-names>AA</given-names></name><name><surname>Ouyang</surname> <given-names>M</given-names></name><name><surname>Galante</surname> <given-names>H</given-names></name><name><surname>Scaglione</surname> <given-names>KM</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ubiquitin-binding site 2 of ataxin-3 prevents its proteasomal degradation by interacting with Rad23</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4638</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5638</pub-id><pub-id pub-id-type="pmid">25144244</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blount</surname> <given-names>JR</given-names></name><name><surname>Libohova</surname> <given-names>K</given-names></name><name><surname>Marsh</surname> <given-names>GB</given-names></name><name><surname>Sutton</surname> <given-names>JR</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Expression and regulation of Deubiquitinase-Resistant, unanchored ubiquitin chains in <italic>Drosophila</italic></article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>8513</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-26364-x</pub-id><pub-id pub-id-type="pmid">29855490</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeddrich</surname> <given-names>A</given-names></name><name><surname>Gaumer</surname> <given-names>S</given-names></name><name><surname>Haacke</surname> <given-names>A</given-names></name><name><surname>Tzvetkov</surname> <given-names>N</given-names></name><name><surname>Albrecht</surname> <given-names>M</given-names></name><name><surname>Evert</surname> <given-names>BO</given-names></name><name><surname>Müller</surname> <given-names>EC</given-names></name><name><surname>Lurz</surname> <given-names>R</given-names></name><name><surname>Breuer</surname> <given-names>P</given-names></name><name><surname>Schugardt</surname> <given-names>N</given-names></name><name><surname>Plassmann</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>K</given-names></name><name><surname>Warrick</surname> <given-names>JM</given-names></name><name><surname>Suopanki</surname> <given-names>J</given-names></name><name><surname>Wüllner</surname> <given-names>U</given-names></name><name><surname>Frank</surname> <given-names>R</given-names></name><name><surname>Hartl</surname> <given-names>UF</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name><name><surname>Wanker</surname> <given-names>EE</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis</article-title><source>The EMBO Journal</source><volume>25</volume><fpage>1547</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601043</pub-id><pub-id pub-id-type="pmid">16525503</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname> <given-names>AH</given-names></name><name><surname>Manoukian</surname> <given-names>AS</given-names></name><name><surname>Perrimon</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Ectopic expression in <italic>Drosophila</italic></article-title><source>Methods in Cell Biology</source><volume>44</volume><fpage>635</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1016/s0091-679x(08)60936-x</pub-id><pub-id pub-id-type="pmid">7707973</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname> <given-names>AH</given-names></name><name><surname>Perrimon</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Targeted gene expression as a means of altering cell fates and generating dominant phenotypes</article-title><source>Development</source><volume>118</volume><fpage>401</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">8223268</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>HY</given-names></name><name><surname>Warrick</surname> <given-names>JM</given-names></name><name><surname>Gray-Board</surname> <given-names>GL</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in <italic>Drosophila</italic></article-title><source>Human Molecular Genetics</source><volume>9</volume><fpage>2811</fpage><lpage>2820</lpage><pub-id pub-id-type="doi">10.1093/hmg/9.19.2811</pub-id><pub-id pub-id-type="pmid">11092757</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>HY</given-names></name><name><surname>Warrick</surname> <given-names>JM</given-names></name><name><surname>Andriola</surname> <given-names>I</given-names></name><name><surname>Merry</surname> <given-names>D</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Genetic modulation of polyglutamine toxicity by protein conjugation pathways in <italic>Drosophila</italic></article-title><source>Human Molecular Genetics</source><volume>11</volume><fpage>2895</fpage><lpage>2904</lpage><pub-id pub-id-type="doi">10.1093/hmg/11.23.2895</pub-id><pub-id pub-id-type="pmid">12393801</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname> <given-names>MC</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Toward understanding Machado-Joseph disease</article-title><source>Progress in Neurobiology</source><volume>97</volume><fpage>239</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2011.11.006</pub-id><pub-id pub-id-type="pmid">22133674</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantuma</surname> <given-names>NP</given-names></name><name><surname>Herzog</surname> <given-names>LK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Machado-Joseph disease: a stress combating deubiquitylating enzyme changing sides</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1233</volume><fpage>237</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-38266-7_10</pub-id><pub-id pub-id-type="pmid">32274760</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname> <given-names>AK</given-names></name><name><surname>Pratt</surname> <given-names>WB</given-names></name><name><surname>Lieberman</surname> <given-names>AP</given-names></name><name><surname>Osawa</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases</article-title><source>Cellular and Molecular Life Sciences</source><volume>77</volume><fpage>977</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03302-2</pub-id><pub-id pub-id-type="pmid">31552448</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dikic</surname> <given-names>I</given-names></name><name><surname>Wakatsuki</surname> <given-names>S</given-names></name><name><surname>Walters</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ubiquitin-binding domains - from structures to functions</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>10</volume><fpage>659</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1038/nrm2767</pub-id><pub-id pub-id-type="pmid">19773779</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname> <given-names>CE</given-names></name><name><surname>An</surname> <given-names>MC</given-names></name><name><surname>Papanikolaou</surname> <given-names>T</given-names></name><name><surname>Rugani</surname> <given-names>C</given-names></name><name><surname>Vitelli</surname> <given-names>C</given-names></name><name><surname>Ellerby</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model</article-title><source>Molecular Neurodegeneration</source><volume>8</volume><elocation-id>42</elocation-id><pub-id pub-id-type="doi">10.1186/1750-1326-8-42</pub-id><pub-id pub-id-type="pmid">24160175</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname> <given-names>EJ</given-names></name><name><surname>Cheetham</surname> <given-names>ME</given-names></name><name><surname>Chapple</surname> <given-names>JP</given-names></name><name><surname>van der Spuy</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease</article-title><source>Sub-Cellular Biochemistry</source><volume>78</volume><fpage>243</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-11731-7_12</pub-id><pub-id pub-id-type="pmid">25487025</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellisdon</surname> <given-names>AM</given-names></name><name><surname>Thomas</surname> <given-names>B</given-names></name><name><surname>Bottomley</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step</article-title><source>Journal of Biological Chemistry</source><volume>281</volume><fpage>16888</fpage><lpage>16896</lpage><pub-id pub-id-type="doi">10.1074/jbc.M601470200</pub-id><pub-id pub-id-type="pmid">16624810</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname> <given-names>CG</given-names></name><name><surname>Chang</surname> <given-names>L</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Heat shock protein 70 (hsp70) as an emerging drug target</article-title><source>Journal of Medicinal Chemistry</source><volume>53</volume><fpage>4585</fpage><lpage>4602</lpage><pub-id pub-id-type="doi">10.1021/jm100054f</pub-id><pub-id pub-id-type="pmid">20334364</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faust</surname> <given-names>O</given-names></name><name><surname>Rosenzweig</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural and biochemical properties of Hsp40/Hsp70 chaperone system</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1243</volume><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-40204-4_1</pub-id><pub-id pub-id-type="pmid">32297208</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figura</surname> <given-names>G</given-names></name><name><surname>Koscianska</surname> <given-names>E</given-names></name><name><surname>Krzyzosiak</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>In vitro expansion of CAG, CAA, and mixed CAG/CAA repeats</article-title><source>International Journal of Molecular Sciences</source><volume>16</volume><fpage>18741</fpage><lpage>18751</lpage><pub-id pub-id-type="doi">10.3390/ijms160818741</pub-id><pub-id pub-id-type="pmid">26270660</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontaine</surname> <given-names>SN</given-names></name><name><surname>Martin</surname> <given-names>MD</given-names></name><name><surname>Akoury</surname> <given-names>E</given-names></name><name><surname>Assimon</surname> <given-names>VA</given-names></name><name><surname>Borysov</surname> <given-names>S</given-names></name><name><surname>Nordhues</surname> <given-names>BA</given-names></name><name><surname>Sabbagh</surname> <given-names>JJ</given-names></name><name><surname>Cockman</surname> <given-names>M</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Zweckstetter</surname> <given-names>M</given-names></name><name><surname>Dickey</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>3971</fpage><lpage>3981</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv135</pub-id><pub-id pub-id-type="pmid">25882706</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giorgetti</surname> <given-names>E</given-names></name><name><surname>Yu</surname> <given-names>Z</given-names></name><name><surname>Chua</surname> <given-names>JP</given-names></name><name><surname>Shimamura</surname> <given-names>R</given-names></name><name><surname>Zhao</surname> <given-names>L</given-names></name><name><surname>Zhu</surname> <given-names>F</given-names></name><name><surname>Venneti</surname> <given-names>S</given-names></name><name><surname>Pennuto</surname> <given-names>M</given-names></name><name><surname>Guan</surname> <given-names>Y</given-names></name><name><surname>Hung</surname> <given-names>G</given-names></name><name><surname>Lieberman</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rescue of metabolic alterations in AR113Q skeletal muscle by peripheral androgen receptor gene silencing</article-title><source>Cell Reports</source><volume>17</volume><fpage>125</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.084</pub-id><pub-id pub-id-type="pmid">27681426</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname> <given-names>EC</given-names></name><name><surname>Motamedi</surname> <given-names>N</given-names></name><name><surname>Lipovsky</surname> <given-names>A</given-names></name><name><surname>Fernández-Busnadiego</surname> <given-names>R</given-names></name><name><surname>DiMaio</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Expression of DNAJB12 or DNAJB14 causes coordinate invasion of the nucleus by membranes associated with a novel nuclear pore structure</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e94322</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0094322</pub-id><pub-id pub-id-type="pmid">24732912</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname> <given-names>KM</given-names></name><name><surname>Linsalata</surname> <given-names>AE</given-names></name><name><surname>Todd</surname> <given-names>PK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RAN translation—What makes it run?</article-title><source>Brain Research</source><volume>1647</volume><fpage>30</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2016.04.003</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groth</surname> <given-names>AC</given-names></name><name><surname>Fish</surname> <given-names>M</given-names></name><name><surname>Nusse</surname> <given-names>R</given-names></name><name><surname>Calos</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Construction of <italic>transgenic Drosophila</italic> by using the site-specific integrase from phage phiC31</article-title><source>Genetics</source><volume>166</volume><fpage>1775</fpage><lpage>1782</lpage><pub-id pub-id-type="doi">10.1534/genetics.166.4.1775</pub-id><pub-id pub-id-type="pmid">15126397</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grove</surname> <given-names>DE</given-names></name><name><surname>Fan</surname> <given-names>CY</given-names></name><name><surname>Ren</surname> <given-names>HY</given-names></name><name><surname>Cyr</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The endoplasmic reticulum-associated Hsp40 DNAJB12 and Hsc70 cooperate to facilitate RMA1 E3-dependent degradation of nascent CFTRDeltaF508</article-title><source>Molecular Biology of the Cell</source><volume>22</volume><fpage>301</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1091/mbc.e10-09-0760</pub-id><pub-id pub-id-type="pmid">21148293</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname> <given-names>GM</given-names></name><name><surname>Dodelzon</surname> <given-names>K</given-names></name><name><surname>Gong</surname> <given-names>L</given-names></name><name><surname>Gonzalez-Alegre</surname> <given-names>P</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e13695</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013695</pub-id><pub-id pub-id-type="pmid">21060878</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iijima-Ando</surname> <given-names>K</given-names></name><name><surname>Wu</surname> <given-names>P</given-names></name><name><surname>Drier</surname> <given-names>EA</given-names></name><name><surname>Iijima</surname> <given-names>K</given-names></name><name><surname>Yin</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>cAMP-response element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity in <italic>Drosophila</italic></article-title><source>PNAS</source><volume>102</volume><fpage>10261</fpage><lpage>10266</lpage><pub-id pub-id-type="doi">10.1073/pnas.0503937102</pub-id><pub-id pub-id-type="pmid">16009936</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinwal</surname> <given-names>UK</given-names></name><name><surname>Miyata</surname> <given-names>Y</given-names></name><name><surname>Koren</surname> <given-names>J</given-names></name><name><surname>Jones</surname> <given-names>JR</given-names></name><name><surname>Trotter</surname> <given-names>JH</given-names></name><name><surname>Chang</surname> <given-names>L</given-names></name><name><surname>O'Leary</surname> <given-names>J</given-names></name><name><surname>Morgan</surname> <given-names>D</given-names></name><name><surname>Lee</surname> <given-names>DC</given-names></name><name><surname>Shults</surname> <given-names>CL</given-names></name><name><surname>Rousaki</surname> <given-names>A</given-names></name><name><surname>Weeber</surname> <given-names>EJ</given-names></name><name><surname>Zuiderweg</surname> <given-names>ER</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Dickey</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Chemical manipulation of hsp70 ATPase activity regulates tau stability</article-title><source>Journal of Neuroscience</source><volume>29</volume><fpage>12079</fpage><lpage>12088</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3345-09.2009</pub-id><pub-id pub-id-type="pmid">19793966</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinwal</surname> <given-names>UK</given-names></name><name><surname>Akoury</surname> <given-names>E</given-names></name><name><surname>Abisambra</surname> <given-names>JF</given-names></name><name><surname>O'Leary</surname> <given-names>JC</given-names></name><name><surname>Thompson</surname> <given-names>AD</given-names></name><name><surname>Blair</surname> <given-names>LJ</given-names></name><name><surname>Jin</surname> <given-names>Y</given-names></name><name><surname>Bacon</surname> <given-names>J</given-names></name><name><surname>Nordhues</surname> <given-names>BA</given-names></name><name><surname>Cockman</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>P</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Borysov</surname> <given-names>S</given-names></name><name><surname>Uversky</surname> <given-names>VN</given-names></name><name><surname>Biernat</surname> <given-names>J</given-names></name><name><surname>Mandelkow</surname> <given-names>E</given-names></name><name><surname>Gestwicki</surname> <given-names>JE</given-names></name><name><surname>Zweckstetter</surname> <given-names>M</given-names></name><name><surname>Dickey</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Imbalance of Hsp70 family variants fosters tau accumulation</article-title><source>The FASEB Journal</source><volume>27</volume><fpage>1450</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1096/fj.12-220889</pub-id><pub-id pub-id-type="pmid">23271055</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>SL</given-names></name><name><surname>Blount</surname> <given-names>JR</given-names></name><name><surname>Libohova</surname> <given-names>K</given-names></name><name><surname>Ranxhi</surname> <given-names>B</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name><name><surname>Tsou</surname> <given-names>W-L</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Differential toxicity of ataxin-3 isoforms in <italic>Drosophila</italic> models of spinocerebellar ataxia type 3</article-title><source>Neurobiology of Disease</source><volume>132</volume><elocation-id>104535</elocation-id><pub-id pub-id-type="doi">10.1016/j.nbd.2019.104535</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampinga</surname> <given-names>HH</given-names></name><name><surname>Bergink</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Heat shock proteins as potential targets for protective strategies in neurodegeneration</article-title><source>The Lancet Neurology</source><volume>15</volume><fpage>748</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(16)00099-5</pub-id><pub-id pub-id-type="pmid">27106072</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawaguchi</surname> <given-names>Y</given-names></name><name><surname>Okamoto</surname> <given-names>T</given-names></name><name><surname>Taniwaki</surname> <given-names>M</given-names></name><name><surname>Aizawa</surname> <given-names>M</given-names></name><name><surname>Inoue</surname> <given-names>M</given-names></name><name><surname>Katayama</surname> <given-names>S</given-names></name><name><surname>Kawakami</surname> <given-names>H</given-names></name><name><surname>Nakamura</surname> <given-names>S</given-names></name><name><surname>Nishimura</surname> <given-names>M</given-names></name><name><surname>Akiguchi</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1</article-title><source>Nature Genetics</source><volume>8</volume><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/ng1194-221</pub-id><pub-id pub-id-type="pmid">7874163</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klement</surname> <given-names>IA</given-names></name><name><surname>Skinner</surname> <given-names>PJ</given-names></name><name><surname>Kaytor</surname> <given-names>MD</given-names></name><name><surname>Yi</surname> <given-names>H</given-names></name><name><surname>Hersch</surname> <given-names>SM</given-names></name><name><surname>Clark</surname> <given-names>HB</given-names></name><name><surname>Zoghbi</surname> <given-names>HY</given-names></name><name><surname>Orr</surname> <given-names>HT</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice</article-title><source>Cell</source><volume>95</volume><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81781-x</pub-id><pub-id pub-id-type="pmid">9778246</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klockgether</surname> <given-names>T</given-names></name><name><surname>Mariotti</surname> <given-names>C</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Spinocerebellar ataxia</article-title><source>Nature Reviews Disease Primers</source><volume>5</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.1038/s41572-019-0074-3</pub-id><pub-id pub-id-type="pmid">30975995</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>LB</given-names></name><name><surname>Yu</surname> <given-names>Z</given-names></name><name><surname>Teng</surname> <given-names>X</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Rna toxicity is a component of ataxin-3 degeneration in <italic>Drosophila</italic></article-title><source>Nature</source><volume>453</volume><fpage>1107</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1038/nature06909</pub-id><pub-id pub-id-type="pmid">18449188</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Jiang</surname> <given-names>Q</given-names></name><name><surname>Bai</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>YF</given-names></name><name><surname>Ruan</surname> <given-names>MY</given-names></name><name><surname>Cai</surname> <given-names>SQ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tetrameric assembly of K<sup>+</sup> channels requires ER-Located chaperone proteins</article-title><source>Molecular Cell</source><volume>65</volume><fpage>52</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.10.027</pub-id><pub-id pub-id-type="pmid">27916661</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname> <given-names>AP</given-names></name><name><surname>Harmison</surname> <given-names>G</given-names></name><name><surname>Strand</surname> <given-names>AD</given-names></name><name><surname>Olson</surname> <given-names>JM</given-names></name><name><surname>Fischbeck</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor</article-title><source>Human Molecular Genetics</source><volume>11</volume><fpage>1967</fpage><lpage>1976</lpage><pub-id pub-id-type="doi">10.1093/hmg/11.17.1967</pub-id><pub-id pub-id-type="pmid">12165558</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname> <given-names>AP</given-names></name><name><surname>Yu</surname> <given-names>Z</given-names></name><name><surname>Murray</surname> <given-names>S</given-names></name><name><surname>Peralta</surname> <given-names>R</given-names></name><name><surname>Low</surname> <given-names>A</given-names></name><name><surname>Guo</surname> <given-names>S</given-names></name><name><surname>Yu</surname> <given-names>XX</given-names></name><name><surname>Cortes</surname> <given-names>CJ</given-names></name><name><surname>Bennett</surname> <given-names>CF</given-names></name><name><surname>Monia</surname> <given-names>BP</given-names></name><name><surname>La Spada</surname> <given-names>AR</given-names></name><name><surname>Hung</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy</article-title><source>Cell Reports</source><volume>7</volume><fpage>774</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.02.008</pub-id><pub-id pub-id-type="pmid">24746732</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname> <given-names>AP</given-names></name><name><surname>Shakkottai</surname> <given-names>VG</given-names></name><name><surname>Albin</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Polyglutamine repeats in neurodegenerative diseases</article-title><source>Annual Review of Pathology: Mechanisms of Disease</source><volume>14</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathmechdis-012418-012857</pub-id><pub-id pub-id-type="pmid">30089230</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeffler</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Influence of normal aging on brain autophagy: a complex scenario</article-title><source>Frontiers in Aging Neuroscience</source><volume>11</volume><elocation-id>49</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2019.00049</pub-id><pub-id pub-id-type="pmid">30914945</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macedo-Ribeiro</surname> <given-names>S</given-names></name><name><surname>Cortes</surname> <given-names>L</given-names></name><name><surname>Maciel</surname> <given-names>P</given-names></name><name><surname>Carvalho</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Nucleocytoplasmic shuttling activity of ataxin-3</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e5834</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0005834</pub-id><pub-id pub-id-type="pmid">19503814</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marmor</surname> <given-names>MD</given-names></name><name><surname>Yarden</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases</article-title><source>Oncogene</source><volume>23</volume><fpage>2057</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207390</pub-id><pub-id pub-id-type="pmid">15021893</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martí</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RNA toxicity induced by expanded CAG repeats in Huntington's disease</article-title><source>Brain Pathology</source><volume>26</volume><fpage>779</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1111/bpa.12427</pub-id><pub-id pub-id-type="pmid">27529325</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masino</surname> <given-names>L</given-names></name><name><surname>Nicastro</surname> <given-names>G</given-names></name><name><surname>Menon</surname> <given-names>RP</given-names></name><name><surname>Dal Piaz</surname> <given-names>F</given-names></name><name><surname>Calder</surname> <given-names>L</given-names></name><name><surname>Pastore</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Characterization of the structure and the amyloidogenic properties of the josephin domain of the polyglutamine-containing protein ataxin-3</article-title><source>Journal of Molecular Biology</source><volume>344</volume><fpage>1021</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2004.09.065</pub-id><pub-id pub-id-type="pmid">15544810</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masino</surname> <given-names>L</given-names></name><name><surname>Nicastro</surname> <given-names>G</given-names></name><name><surname>De Simone</surname> <given-names>A</given-names></name><name><surname>Calder</surname> <given-names>L</given-names></name><name><surname>Molloy</surname> <given-names>J</given-names></name><name><surname>Pastore</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The josephin domain determines the morphological and mechanical properties of ataxin-3 fibrils</article-title><source>Biophysical Journal</source><volume>100</volume><fpage>2033</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2011.02.056</pub-id><pub-id pub-id-type="pmid">21504740</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monsellier</surname> <given-names>E</given-names></name><name><surname>Redeker</surname> <given-names>V</given-names></name><name><surname>Ruiz-Arlandis</surname> <given-names>G</given-names></name><name><surname>Bousset</surname> <given-names>L</given-names></name><name><surname>Melki</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Molecular interaction between the chaperone Hsc70 and the N-terminal flank of huntingtin exon 1 modulates aggregation</article-title><source>Journal of Biological Chemistry</source><volume>290</volume><fpage>2560</fpage><lpage>2576</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.603332</pub-id><pub-id pub-id-type="pmid">25505179</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname> <given-names>SR</given-names></name><name><surname>Lieberman</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The Ubiquitination, disaggregation and proteasomal degradation machineries in polyglutamine disease</article-title><source>Frontiers in Molecular Neuroscience</source><volume>10</volume><elocation-id>78</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2017.00078</pub-id><pub-id pub-id-type="pmid">28381987</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicastro</surname> <given-names>G</given-names></name><name><surname>Menon</surname> <given-names>RP</given-names></name><name><surname>Masino</surname> <given-names>L</given-names></name><name><surname>Knowles</surname> <given-names>PP</given-names></name><name><surname>McDonald</surname> <given-names>NQ</given-names></name><name><surname>Pastore</surname> <given-names>A</given-names></name></person-group><article-title>The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition</article-title><source>PNAS</source><year iso-8601-date="2005">2005</year><volume>102</volume><fpage>10493</fpage><lpage>10501</lpage></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicastro</surname> <given-names>G</given-names></name><name><surname>Masino</surname> <given-names>L</given-names></name><name><surname>Esposito</surname> <given-names>V</given-names></name><name><surname>Menon</surname> <given-names>RP</given-names></name><name><surname>De Simone</surname> <given-names>A</given-names></name><name><surname>Fraternali</surname> <given-names>F</given-names></name><name><surname>Pastore</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Josephin domain of ataxin-3 contains two distinct ubiquitin-binding sites</article-title><source>Biopolymers</source><volume>91</volume><fpage>1203</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1002/bip.21210</pub-id><pub-id pub-id-type="pmid">19382171</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicastro</surname> <given-names>G</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name><name><surname>Karaca</surname> <given-names>E</given-names></name><name><surname>Bonvin</surname> <given-names>AM</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name><name><surname>Pastore</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Understanding the role of the josephin domain in the PolyUb binding and cleavage properties of ataxin-3</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e12430</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012430</pub-id><pub-id pub-id-type="pmid">20865150</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname> <given-names>L</given-names></name><name><surname>Singh</surname> <given-names>GK</given-names></name><name><surname>Osterwalder</surname> <given-names>T</given-names></name><name><surname>Roman</surname> <given-names>GW</given-names></name><name><surname>Davis</surname> <given-names>RL</given-names></name><name><surname>Keshishian</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Spatial and temporal control of gene expression in <italic>Drosophila</italic> using the inducible GeneSwitch GAL4 system. I. screen for larval nervous system drivers</article-title><source>Genetics</source><volume>178</volume><fpage>215</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1534/genetics.107.081968</pub-id><pub-id pub-id-type="pmid">18202369</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterwalder</surname> <given-names>T</given-names></name><name><surname>Yoon</surname> <given-names>KS</given-names></name><name><surname>White</surname> <given-names>BH</given-names></name><name><surname>Keshishian</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A conditional tissue-specific transgene expression system using inducible GAL4</article-title><source>PNAS</source><volume>98</volume><fpage>12596</fpage><lpage>12601</lpage><pub-id pub-id-type="doi">10.1073/pnas.221303298</pub-id><pub-id pub-id-type="pmid">11675495</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulson</surname> <given-names>HL</given-names></name><name><surname>Perez</surname> <given-names>MK</given-names></name><name><surname>Trottier</surname> <given-names>Y</given-names></name><name><surname>Trojanowski</surname> <given-names>JQ</given-names></name><name><surname>Subramony</surname> <given-names>SH</given-names></name><name><surname>Das</surname> <given-names>SS</given-names></name><name><surname>Vig</surname> <given-names>P</given-names></name><name><surname>Mandel</surname> <given-names>JL</given-names></name><name><surname>Fischbeck</surname> <given-names>KH</given-names></name><name><surname>Pittman</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Intranuclear inclusions of expanded polyglutamine protein in Spinocerebellar Ataxia type 3</article-title><source>Neuron</source><volume>19</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(00)80943-5</pub-id><pub-id pub-id-type="pmid">9292723</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez Ortiz</surname> <given-names>JM</given-names></name><name><surname>Orr</surname> <given-names>HT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spinocerebellar ataxia type 1: molecular mechanisms of neurodegeneration and preclinical studies</article-title><source>Advances in Experimental Medicine and Biology</source><volume>1049</volume><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-71779-1_6</pub-id><pub-id pub-id-type="pmid">29427101</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ristic</surname> <given-names>G</given-names></name><name><surname>Sutton</surname> <given-names>JR</given-names></name><name><surname>Libohova</surname> <given-names>K</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Toxicity and aggregation of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila Melanogaster</article-title><source>Neurobiology of Disease</source><volume>116</volume><fpage>78</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2018.04.013</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname> <given-names>G</given-names></name><name><surname>Jacquel</surname> <given-names>A</given-names></name><name><surname>Auberger</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chaperone-Mediated autophagy and its emerging role in hematological malignancies</article-title><source>Cells</source><volume>8</volume><elocation-id>1260</elocation-id><pub-id pub-id-type="doi">10.3390/cells8101260</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname> <given-names>G</given-names></name><name><surname>Davis</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Conditional expression of UAS-transgenes in the adult eye with a new gene-switch vector system</article-title><source>Genesis</source><volume>34</volume><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1002/gene.10133</pub-id><pub-id pub-id-type="pmid">12324966</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scior</surname> <given-names>A</given-names></name><name><surname>Buntru</surname> <given-names>A</given-names></name><name><surname>Arnsburg</surname> <given-names>K</given-names></name><name><surname>Ast</surname> <given-names>A</given-names></name><name><surname>Iburg</surname> <given-names>M</given-names></name><name><surname>Juenemann</surname> <given-names>K</given-names></name><name><surname>Pigazzini</surname> <given-names>ML</given-names></name><name><surname>Mlody</surname> <given-names>B</given-names></name><name><surname>Puchkov</surname> <given-names>D</given-names></name><name><surname>Priller</surname> <given-names>J</given-names></name><name><surname>Wanker</surname> <given-names>EE</given-names></name><name><surname>Prigione</surname> <given-names>A</given-names></name><name><surname>Kirstein</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Complete suppression of htt fibrilization and disaggregation of htt fibrils by a trimeric chaperone complex</article-title><source>The EMBO Journal</source><volume>37</volume><fpage>282</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.15252/embj.201797212</pub-id><pub-id pub-id-type="pmid">29212816</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serlidaki</surname> <given-names>D</given-names></name><name><surname>van Waarde</surname> <given-names>M</given-names></name><name><surname>Rohland</surname> <given-names>L</given-names></name><name><surname>Wentink</surname> <given-names>AS</given-names></name><name><surname>Dekker</surname> <given-names>SL</given-names></name><name><surname>Kamphuis</surname> <given-names>MJ</given-names></name><name><surname>Boertien</surname> <given-names>JM</given-names></name><name><surname>Brunsting</surname> <given-names>JF</given-names></name><name><surname>Nillegoda</surname> <given-names>NB</given-names></name><name><surname>Bukau</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Functional diversity between HSP70 paralogs due to variable interactions with specific co-chaperones</article-title><source>The Journal of Biological Chemistry</source><volume>13</volume><elocation-id>012449</elocation-id><pub-id pub-id-type="doi">10.1074/jbc.RA119.012449</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shieh</surname> <given-names>SY</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Genes and pathways affected by CAG-repeat RNA-based toxicity in <italic>Drosophila</italic></article-title><source>Human Molecular Genetics</source><volume>20</volume><fpage>4810</fpage><lpage>4821</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr420</pub-id><pub-id pub-id-type="pmid">21933837</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobczak</surname> <given-names>K</given-names></name><name><surname>de Mezer</surname> <given-names>M</given-names></name><name><surname>Michlewski</surname> <given-names>G</given-names></name><name><surname>Krol</surname> <given-names>J</given-names></name><name><surname>Krzyzosiak</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>RNA structure of trinucleotide repeats associated with human neurological diseases</article-title><source>Nucleic Acids Research</source><volume>31</volume><fpage>5469</fpage><lpage>5482</lpage><pub-id pub-id-type="doi">10.1093/nar/gkg766</pub-id><pub-id pub-id-type="pmid">14500809</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobczak</surname> <given-names>K</given-names></name><name><surname>Krzyzosiak</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>CAG repeats containing CAA interruptions form branched hairpin structures in spinocerebellar ataxia type 2 transcripts</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>3898</fpage><lpage>3910</lpage><pub-id pub-id-type="doi">10.1074/jbc.M409984200</pub-id><pub-id pub-id-type="pmid">15533937</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sopha</surname> <given-names>P</given-names></name><name><surname>Kadokura</surname> <given-names>H</given-names></name><name><surname>Yamamoto</surname> <given-names>YH</given-names></name><name><surname>Takeuchi</surname> <given-names>M</given-names></name><name><surname>Saito</surname> <given-names>M</given-names></name><name><surname>Tsuru</surname> <given-names>A</given-names></name><name><surname>Kohno</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A novel mammalian ER-located J-protein, DNAJB14, can accelerate ERAD of misfolded membrane proteins</article-title><source>Cell Structure and Function</source><volume>37</volume><fpage>177</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1247/csf.12017</pub-id><pub-id pub-id-type="pmid">23018488</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stochmanski</surname> <given-names>SJ</given-names></name><name><surname>Therrien</surname> <given-names>M</given-names></name><name><surname>Laganière</surname> <given-names>J</given-names></name><name><surname>Rochefort</surname> <given-names>D</given-names></name><name><surname>Laurent</surname> <given-names>S</given-names></name><name><surname>Karemera</surname> <given-names>L</given-names></name><name><surname>Gaudet</surname> <given-names>R</given-names></name><name><surname>Vyboh</surname> <given-names>K</given-names></name><name><surname>Van Meyel</surname> <given-names>DJ</given-names></name><name><surname>Di Cristo</surname> <given-names>G</given-names></name><name><surname>Dion</surname> <given-names>PA</given-names></name><name><surname>Gaspar</surname> <given-names>C</given-names></name><name><surname>Rouleau</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Expanded ATXN3 frameshifting events are toxic in <italic>Drosophila</italic> and mammalian neuron models</article-title><source>Human Molecular Genetics</source><volume>21</volume><fpage>2211</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds036</pub-id><pub-id pub-id-type="pmid">22337953</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stricher</surname> <given-names>F</given-names></name><name><surname>Macri</surname> <given-names>C</given-names></name><name><surname>Ruff</surname> <given-names>M</given-names></name><name><surname>Muller</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HSPA8/HSC70 chaperone protein: structure, function, and chemical targeting</article-title><source>Autophagy</source><volume>9</volume><fpage>1937</fpage><lpage>1954</lpage><pub-id pub-id-type="doi">10.4161/auto.26448</pub-id><pub-id pub-id-type="pmid">24121476</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sujkowski</surname> <given-names>A</given-names></name><name><surname>Bazzell</surname> <given-names>B</given-names></name><name><surname>Carpenter</surname> <given-names>K</given-names></name><name><surname>Arking</surname> <given-names>R</given-names></name><name><surname>Wessells</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Endurance exercise and selective breeding for longevity extend <italic>Drosophila</italic> healthspan by overlapping mechanisms</article-title><source>Aging</source><volume>7</volume><fpage>535</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.18632/aging.100789</pub-id><pub-id pub-id-type="pmid">26298685</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutton</surname> <given-names>JR</given-names></name><name><surname>Blount</surname> <given-names>JR</given-names></name><name><surname>Libohova</surname> <given-names>K</given-names></name><name><surname>Tsou</surname> <given-names>WL</given-names></name><name><surname>Joshi</surname> <given-names>GS</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name><name><surname>Costa</surname> <given-names>MDC</given-names></name><name><surname>Scaglione</surname> <given-names>KM</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in <italic>Drosophila</italic> models of Spinocerebellar Ataxia Type 3</article-title><source>Human Molecular Genetics</source><volume>26</volume><fpage>1419</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx039</pub-id><pub-id pub-id-type="pmid">28158474</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayama</surname> <given-names>S</given-names></name><name><surname>Xie</surname> <given-names>Z</given-names></name><name><surname>Reed</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone regulators</article-title><source>Journal of Biological Chemistry</source><volume>274</volume><fpage>781</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.2.781</pub-id><pub-id pub-id-type="pmid">9873016</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiruvalluvan</surname> <given-names>A</given-names></name><name><surname>de Mattos</surname> <given-names>EP</given-names></name><name><surname>Brunsting</surname> <given-names>JF</given-names></name><name><surname>Bakels</surname> <given-names>R</given-names></name><name><surname>Serlidaki</surname> <given-names>D</given-names></name><name><surname>Barazzuol</surname> <given-names>L</given-names></name><name><surname>Conforti</surname> <given-names>P</given-names></name><name><surname>Fatima</surname> <given-names>A</given-names></name><name><surname>Koyuncu</surname> <given-names>S</given-names></name><name><surname>Cattaneo</surname> <given-names>E</given-names></name><name><surname>Vilchez</surname> <given-names>D</given-names></name><name><surname>Bergink</surname> <given-names>S</given-names></name><name><surname>Boddeke</surname> <given-names>E</given-names></name><name><surname>Copray</surname> <given-names>S</given-names></name><name><surname>Kampinga</surname> <given-names>HH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DNAJB6, a key factor in neuronal sensitivity to amyloidogenesis</article-title><source>Molecular Cell</source><volume>78</volume><fpage>346</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.02.022</pub-id><pub-id pub-id-type="pmid">32268123</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todi</surname> <given-names>SV</given-names></name><name><surname>Laco</surname> <given-names>MN</given-names></name><name><surname>Winborn</surname> <given-names>BJ</given-names></name><name><surname>Travis</surname> <given-names>SM</given-names></name><name><surname>Wen</surname> <given-names>HM</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2007">2007a</year><article-title>Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity</article-title><source>Journal of Biological Chemistry</source><volume>282</volume><fpage>29348</fpage><lpage>29358</lpage><pub-id pub-id-type="doi">10.1074/jbc.M704126200</pub-id><pub-id pub-id-type="pmid">17693639</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Todi</surname> <given-names>SV</given-names></name><name><surname>Williams</surname> <given-names>AJ</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2007">2007b</year><chapter-title>Polyglutamine Disorders Including Huntington's Disease</chapter-title><person-group person-group-type="editor"><name><surname>Waxman</surname> <given-names>S. G</given-names></name></person-group><source>Molecular Neurology</source><publisher-name>Academic Press</publisher-name><fpage>257</fpage><lpage>276</lpage></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todi</surname> <given-names>SV</given-names></name><name><surname>Winborn</surname> <given-names>BJ</given-names></name><name><surname>Scaglione</surname> <given-names>KM</given-names></name><name><surname>Blount</surname> <given-names>JR</given-names></name><name><surname>Travis</surname> <given-names>SM</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3</article-title><source>The EMBO Journal</source><volume>28</volume><fpage>372</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1038/emboj.2008.289</pub-id><pub-id pub-id-type="pmid">19153604</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todi</surname> <given-names>SV</given-names></name><name><surname>Scaglione</surname> <given-names>KM</given-names></name><name><surname>Blount</surname> <given-names>JR</given-names></name><name><surname>Basrur</surname> <given-names>V</given-names></name><name><surname>Conlon</surname> <given-names>KP</given-names></name><name><surname>Pastore</surname> <given-names>A</given-names></name><name><surname>Elenitoba-Johnson</surname> <given-names>K</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>39303</fpage><lpage>39313</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.181610</pub-id><pub-id pub-id-type="pmid">20943656</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname> <given-names>WL</given-names></name><name><surname>Burr</surname> <given-names>AA</given-names></name><name><surname>Ouyang</surname> <given-names>M</given-names></name><name><surname>Blount</surname> <given-names>JR</given-names></name><name><surname>Scaglione</surname> <given-names>KM</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ubiquitination regulates the neuroprotective function of the deubiquitinase ataxin-3 in vivo</article-title><source>Journal of Biological Chemistry</source><volume>288</volume><fpage>34460</fpage><lpage>34469</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.513903</pub-id><pub-id pub-id-type="pmid">24106274</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname> <given-names>WL</given-names></name><name><surname>Ouyang</surname> <given-names>M</given-names></name><name><surname>Hosking</surname> <given-names>RR</given-names></name><name><surname>Sutton</surname> <given-names>JR</given-names></name><name><surname>Blount</surname> <given-names>JR</given-names></name><name><surname>Burr</surname> <given-names>AA</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in <italic>Drosophila melanogaster</italic></article-title><source>Neurobiology of Disease</source><volume>82</volume><fpage>12</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2015.05.010</pub-id><pub-id pub-id-type="pmid">26007638</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname> <given-names>WL</given-names></name><name><surname>Hosking</surname> <given-names>RR</given-names></name><name><surname>Burr</surname> <given-names>AA</given-names></name><name><surname>Sutton</surname> <given-names>JR</given-names></name><name><surname>Ouyang</surname> <given-names>M</given-names></name><name><surname>Du</surname> <given-names>X</given-names></name><name><surname>Gomez</surname> <given-names>CM</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>DnaJ-1 and karyopherin α3 suppress degeneration in a new <italic>Drosophila</italic> model of spinocerebellar ataxia type 6</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>4385</fpage><lpage>4396</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv174</pub-id><pub-id pub-id-type="pmid">25954029</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname> <given-names>WL</given-names></name><name><surname>Qiblawi</surname> <given-names>SH</given-names></name><name><surname>Hosking</surname> <given-names>RR</given-names></name><name><surname>Gomez</surname> <given-names>CM</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Polyglutamine length-dependent toxicity from α1act in <italic>Drosophila</italic> models of spinocerebellar ataxia type 6</article-title><source>Biology Open</source><volume>5</volume><fpage>1770</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1242/bio.021667</pub-id><pub-id pub-id-type="pmid">27979829</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vossfeldt</surname> <given-names>H</given-names></name><name><surname>Butzlaff</surname> <given-names>M</given-names></name><name><surname>PrüSSing</surname> <given-names>K</given-names></name><name><surname>Ní Chárthaigh</surname> <given-names>RA</given-names></name><name><surname>Karsten</surname> <given-names>P</given-names></name><name><surname>Lankes</surname> <given-names>A</given-names></name><name><surname>Hamm</surname> <given-names>S</given-names></name><name><surname>Simons</surname> <given-names>M</given-names></name><name><surname>Adryan</surname> <given-names>B</given-names></name><name><surname>Schulz</surname> <given-names>JB</given-names></name><name><surname>Voigt</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Large-scale screen for modifiers of ataxin-3-derived polyglutamine-induced toxicity in <italic>Drosophila</italic></article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e47452</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0047452</pub-id><pub-id pub-id-type="pmid">23139745</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warrick</surname> <given-names>JM</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name><name><surname>Gray-Board</surname> <given-names>GL</given-names></name><name><surname>Bui</surname> <given-names>QT</given-names></name><name><surname>Fischbeck</surname> <given-names>KH</given-names></name><name><surname>Pittman</surname> <given-names>RN</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in <italic>Drosophila</italic></article-title><source>Cell</source><volume>93</volume><fpage>939</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81200-3</pub-id><pub-id pub-id-type="pmid">9635424</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warrick</surname> <given-names>JM</given-names></name><name><surname>Chan</surname> <given-names>HY</given-names></name><name><surname>Gray-Board</surname> <given-names>GL</given-names></name><name><surname>Chai</surname> <given-names>Y</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Suppression of polyglutamine-mediated neurodegeneration in <italic>Drosophila</italic> by the molecular chaperone HSP70</article-title><source>Nature Genetics</source><volume>23</volume><fpage>425</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1038/70532</pub-id><pub-id pub-id-type="pmid">10581028</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warrick</surname> <given-names>JM</given-names></name><name><surname>Morabito</surname> <given-names>LM</given-names></name><name><surname>Bilen</surname> <given-names>J</given-names></name><name><surname>Gordesky-Gold</surname> <given-names>B</given-names></name><name><surname>Faust</surname> <given-names>LZ</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name><name><surname>Bonini</surname> <given-names>NM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Ataxin-3 suppresses polyglutamine neurodegeneration in <italic>Drosophila</italic> by a ubiquitin-associated mechanism</article-title><source>Molecular Cell</source><volume>18</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.02.030</pub-id><pub-id pub-id-type="pmid">15808507</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winborn</surname> <given-names>BJ</given-names></name><name><surname>Travis</surname> <given-names>SM</given-names></name><name><surname>Todi</surname> <given-names>SV</given-names></name><name><surname>Scaglione</surname> <given-names>KM</given-names></name><name><surname>Xu</surname> <given-names>P</given-names></name><name><surname>Williams</surname> <given-names>AJ</given-names></name><name><surname>Cohen</surname> <given-names>RE</given-names></name><name><surname>Peng</surname> <given-names>J</given-names></name><name><surname>Paulson</surname> <given-names>HL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains</article-title><source>Journal of Biological Chemistry</source><volume>283</volume><fpage>26436</fpage><lpage>26443</lpage><pub-id pub-id-type="doi">10.1074/jbc.M803692200</pub-id><pub-id pub-id-type="pmid">18599482</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname> <given-names>YH</given-names></name><name><surname>Kimura</surname> <given-names>T</given-names></name><name><surname>Momohara</surname> <given-names>S</given-names></name><name><surname>Takeuchi</surname> <given-names>M</given-names></name><name><surname>Tani</surname> <given-names>T</given-names></name><name><surname>Kimata</surname> <given-names>Y</given-names></name><name><surname>Kadokura</surname> <given-names>H</given-names></name><name><surname>Kohno</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A novel ER J-protein DNAJB12 accelerates ER-associated degradation of membrane proteins including CFTR</article-title><source>Cell Structure and Function</source><volume>35</volume><fpage>107</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1247/csf.10023</pub-id><pub-id pub-id-type="pmid">21150129</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Binari</surname> <given-names>R</given-names></name><name><surname>Zhou</surname> <given-names>R</given-names></name><name><surname>Perrimon</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A genomewide RNA interference screen for modifiers of aggregates formation by mutant huntingtin in <italic>Drosophila</italic></article-title><source>Genetics</source><volume>184</volume><fpage>1165</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1534/genetics.109.112516</pub-id><pub-id pub-id-type="pmid">20100940</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>N</given-names></name><name><surname>Shabek</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ubiquitin ligases: structure, function, and regulation</article-title><source>Annual Review of Biochemistry</source><volume>86</volume><fpage>129</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060815-014922</pub-id><pub-id pub-id-type="pmid">28375744</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname> <given-names>T</given-names></name><name><surname>Gibbens</surname> <given-names>B</given-names></name><name><surname>Doty</surname> <given-names>NS</given-names></name><name><surname>Gomes-Pereira</surname> <given-names>M</given-names></name><name><surname>Huguet</surname> <given-names>A</given-names></name><name><surname>Stone</surname> <given-names>MD</given-names></name><name><surname>Margolis</surname> <given-names>J</given-names></name><name><surname>Peterson</surname> <given-names>M</given-names></name><name><surname>Markowski</surname> <given-names>TW</given-names></name><name><surname>Ingram</surname> <given-names>MA</given-names></name><name><surname>Nan</surname> <given-names>Z</given-names></name><name><surname>Forster</surname> <given-names>C</given-names></name><name><surname>Low</surname> <given-names>WC</given-names></name><name><surname>Schoser</surname> <given-names>B</given-names></name><name><surname>Somia</surname> <given-names>NV</given-names></name><name><surname>Clark</surname> <given-names>HB</given-names></name><name><surname>Schmechel</surname> <given-names>S</given-names></name><name><surname>Bitterman</surname> <given-names>PB</given-names></name><name><surname>Gourdon</surname> <given-names>G</given-names></name><name><surname>Swanson</surname> <given-names>MS</given-names></name><name><surname>Moseley</surname> <given-names>M</given-names></name><name><surname>Ranum</surname> <given-names>LP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Non-ATG-initiated translation directed by microsatellite expansions</article-title><source>PNAS</source><volume>108</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1073/pnas.1013343108</pub-id><pub-id pub-id-type="pmid">21173221</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname> <given-names>T</given-names></name><name><surname>Pattamatta</surname> <given-names>A</given-names></name><name><surname>Ranum</surname> <given-names>LPW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Repeat-Associated Non-ATG translation in neurological diseases</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>10</volume><elocation-id>a033019</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a033019</pub-id><pub-id pub-id-type="pmid">29891563</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60742.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>VijayRaghavan</surname><given-names>K</given-names></name><role>Reviewing Editor</role><aff><institution>National Centre for Biological Sciences, Tata Institute of Fundamental Research</institution><country>India</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Albin</surname><given-names>Roger</given-names> </name><role>Reviewer</role></contrib><contrib contrib-type="reviewer"><name><surname>Pandey</surname><given-names>Udai</given-names> </name><role>Reviewer</role><aff><institution>University of Pittsburgh</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This is an interesting manuscript describing manipulation of Ataxin-3 UIMs in fly models of SCA3. Following up their own prior work, the authors present good evidence that UIMs, which comprise a substantial fraction of Ataxin-3, modulate Ataxin-3 polyQ toxicity. These findings are notable as they indicate how specific features of expanded polyQ containing proteins produce distinct phenotypes. In a counter-intuitive finding, a key actor appears to be interactions with the chaperone protein HSC-70-4. Overall, the work is well done, well presented, and well illustrated.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Ubiquitin-interacting motifs of ataxin-3 regulate its polyglutamine toxicity through Hsc70-4-dependent aggregation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by K VijayRaghavan as the Senior and Reviewing Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Roger Albin (Reviewer #1); Udai Pandey (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>Summary:</p><p>This is an interesting manuscript describing manipulation of Ataxin-3 UIMs in fly models of SCA3. Following up their own prior, nice work, the authors present good evidence that UIMs, which comprise a substantial fraction of Ataxin-3, modulate Ataxin-3 polyQ toxicity. These findings are notable as they indicate how specific features of expanded polyQ containing proteins produce distinct phenotypes. In a counter-intuitive finding, a key actor appears to be interactions with the chaperone protein HSC-70-4. Overall, the work is well done, well presented, and will illustrated.</p><p>Essential revisions:</p><p>I have one significant concern:</p><p>1) The authors also describe HSC-70-4 depletion as ameliorating pure polyQ toxicity. They have good data that UIM interactions are important in HSC-70-4 effects on the full transgene but how don't they know both mechanisms are operative.</p><p>2) The Q80-UIMs appears to be highly toxic than the QIM1-2-Q80-UIM3s in Figure 2D but the Q80-UIMs Seems to be living longer than QIM1-2-Q80-UIM3s Figure 2E. Can the author provide an explanation for this? One would assume that the more toxic a protein the more impact it should have on survival.</p><p>3) Since it is known that polyQ-expanded repeats sequester ubiquitin conjugates into aggregates, does mutating UIM (SCA3UIM*) decrease this since it is less aggregate prone in the two assays done in Figure 4? Does reducing Hsc70-4 have any effect on polyQ-expanded repeats-Mediated ubiquitin conjugates aggregation?</p><p>4) Figure 1—figure supplement 1 includes negative geotaxis assay that was never mentioned in the Results. The authors also mention in the Results &quot;Also, there was no statistical difference between controls and lies expressing SCA3 (VBM*)&quot; without mentioning what they are referring to in Figure 1—figure supplement 1, is it Figure 1—figure supplement 1A and B or both? Please make this clear.</p><p>5) What are the expression levels of the different construct in Figure 2D?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.60742.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>I have one significant concern:</p><p>1) The authors also describe HSC-70-4 depletion as ameliorating pure polyQ toxicity. They have good data that UIM interactions are important in HSC-70-4 effects on the full transgene but how don't they know both mechanisms are operative.</p></disp-quote><p>This is an important detail and we agree. We hope that the clarification below, in the Discussion, addresses this point.</p><p>&quot;How might Hsc70-4 worsen polyQ fragment toxicity? […] Nevertheless, we cannot fully discount the possibility that Hsc70-4 activities on the SCA3 protein may also depend on polyQ-based interactions, once UIM-based binding is established. At this point, the primary takeaway is that Hsc70-4 can enhance polyQ toxicity, in the case of ataxin-3 through its UIMs.&quot;</p><disp-quote content-type="editor-comment"><p>2) The Q80-UIMs appears to be highly toxic than the QIM1-2-Q80-UIM3s in Figure 2D but the Q80-UIMs Seems to be living longer than QIM1-2-Q80-UIM3s Figure 2E. Can the author provide an explanation for this? One would assume that the more toxic a protein the more impact it should have on survival.</p></disp-quote><p>Thank you for this important detail. We believe that this comment is referring to Q80-UIM3. In the prior version of the manuscript we alluded to tissue-specific differences based on data from neuronal and glial cells. We have now further expanded on this point in the Results, with the following added text:</p><p>&quot;There were tissue-dependent variations in toxicity from the above constructs. For example, Q80-UIM3 was markedly more toxic in fly eyes compared to the polyQ80 alone or with the addition of other UIMs (Figure 2D), whereas polyQ80 with all three UIMs was the most toxic species in adult neurons (Figure 2E). […] These outcomes highlight the utility of the new fly models that we have generated to understand tissue-selective toxicity in vivo in the future.&quot;</p><disp-quote content-type="editor-comment"><p>3) Since it is known that polyQ-expanded repeats sequester ubiquitin conjugates into aggregates, does mutating UIM (SCA3UIM*) decrease this since it is less aggregate prone in the two assays done in Figure 4? Does reducing Hsc70-4 have any effect on polyQ-expanded repeats-Mediated ubiquitin conjugates aggregation?</p></disp-quote><p>At present, we do not know the impact the UIMs might have on ataxin-3 inclusions and their decoration by endogenous ubiquitin. We know that ataxin-3 with mutated UIMs is itself less readily ubiquitinated (published work and other studies that we have not yet consolidated into a story; Todi et al., 2009; Todi et al., 2010). Whether this effect impacts the decoration of atxn3 aggregates is not clear at this time and is something we should investigate.</p><disp-quote content-type="editor-comment"><p>4) Figure 1—figure supplement 1 includes negative geotaxis assay that was never mentioned in the Results. The authors also mention in the Results &quot;Also, there was no statistical difference between controls and lies expressing SCA3 (VBM*)&quot; without mentioning what they are referring to in Figure 1—figure supplement 1, is it Figure 1—figure supplement 1A and B or both? Please make this clear.</p></disp-quote><p>We apologize for the lack of clarity in this part of the manuscript. We have amended it as follows in the Results:</p><p>&quot;Next, we examined the effect of the same ataxin-3 transgenes in glial cells to obtain information on toxicity from pathogenic ataxin-3 in this cell type. […] There was no statistical difference between controls not expressing pathogenic ataxin-3 and flies expressing pathogenic ataxin-3 with mutated VBM both in terms of longevity (Figure 1—figure supplement 1A) and motility (Figure 1—figure supplement 1B). These findings highlight a need to explore the role of glia in SCA3.&quot;</p><disp-quote content-type="editor-comment"><p>5) What are the expression levels of the different construct in Figure 2D?</p></disp-quote><p>Overall levels are shown in Figure 2—figure supplement 1. Results are from whole, dissected fly heads. We caution here that the comparison of overall polyQ protein levels is not precise, especially concerning polyQ80-UIM3, which leads to markedly severe eye degeneration. The driving reason for generating these truncated lines was to conduct an initial exploration of the role of UIMs on the isolated polyQ of ataxin-3. The main focus of the present work is full-length ataxin-3 and the role of the UIMs in its pathogenicity, explored in subsequent figures. Future work will dissect how individual UIMs impact various properties of the isolated polyQ80 in a tissue- and age-dependent manner.</p></body></sub-article></article>